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1. INTRODUCTION: ALZHEIMER’S DISEASE FROM A
CHEMIST’S POINT OF VIEW
1.1. Deﬁnitions and Symptoms
Alzheimer’s disease (AD)1−3 is the most common form of
dementia (estimated ∼50−60% of all cases), associated with
loss of memory (in particular episodic memory), cognitive
decline, and behavioral and physical disability, ultimately
leading to death.4−6 It is the sixth most common cause of
death in the US according to the Alzheimer’s Association, and
more than 5 million Americans suﬀered from the disease in
2011, with prevalence growing steadily.7 A large body of recent
research, to be reviewed herein, has put the AD ﬁeld into
contact with bioinorganic chemistry, and this review will
attempt to present the growing role of bioinorganic chemistry
in AD research, with a particular emphasis on zinc homeostasis.
The two main histopathological criteria for AD are
observations of extracellular deposits of ﬁbrillar peptides called
senile plaques and of widespread intraneuronal ﬁbrillar tangles.
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The senile plaques are formed from ∼40-residue fragments,
known as β-amyloids (Aβ), of the transmembrane amyloid
precursor protein (APP) found in the membranes of cells and
organelles such as mitochondria;4,5 thus, recent reports show
that Aβ also accumulates intracellularly.8 The neuroﬁbrillar
tangles consist of twisted strands of hyperphosphorylated tau
protein, a protein that is important for the structural integrity of
microtubules, structural tubulin polymers of the cytoskeleton of
the neurons,4 and are thus commonly observed upon
neurodegeneration. Amyloid plaques are also not unique to
AD, because 20−40% of unaﬀected elderly individuals possess
amyloid plaques suﬃcient for post-mortem AD diagnosis,9
showing that the disease requires a clarifying and unifying
pathogenic understanding.
Other observations consistently relating to AD brains are (1)
loss of neurons and synapses in the cerebral cortex, involved in
memory and cognition, and in particular in the hippocampus
(part of the limbic system), playing a key role in memory,10 (2)
oxidized biomolecules reminiscent of oxidative stress,11,12 (3)
impaired energy metabolism and reduced glucose uptake,13 (4)
altered calcium,5 iron,14,15 zinc,16 and copper17 homeo-
stasis,18,19 (5) diabetes-like pathologies,20,21 and (6) elevated
homocysteine22−24 and abnormal expression of homeostatic
metalloproteins such as metallothioneins.25 As will be
discussed, all of these pathological changes have relations to
metal ion homeostasis that may point toward underlying
common causes of AD.
Cognitive and behavioral symptoms associated with AD6,26
include (1) mild cognitive impairment (MCI) before actual AD
diagnosis,4,27 (2) progressive impairment of activities of daily
living, (3) enhanced risk of depression,28,29 (4) memory loss, in
particular loss of episodic memory, that is, memory associated
with own life experiences, distinguishing AD from other types
of dementia,26 (5) loss of identity,30 and (6) ending with severe
and global impairment of cognition and mobility.10,26
1.2. Risk Factors
AD is a complex disease, mostly occurring sporadically with no
apparent inheritance31 and with age as the main risk factor.4
The perceived complexity of AD implies that the disease has a
broad clinical spectrum6 aggravated by a multitude of genetic
and environmental factors and is aﬀected by many genes of
small but cumulative signiﬁcance.4,32,33 Exogenous risk factors
include (1) brain trauma,7 (2) smoking,29,34 (3) obesity,35,36
(4) diabetes,4,37 (5) hypertension,29,38 (6) cholesterol,39,40 (7)
elevated homocysteine levels (hyperhomocysteinemia),22,24 and
(8) exogenous metal exposure,41 including lead,42 mercury,43
and aluminum.44−47
Genetic risk factors are now known to cause AD in rare cases,
most notably due to mutations in APP or presenilin,48 which is
a constituent of the γ-secretase enzyme complex that degrades
APP into Aβ giving rise to familial AD,5 and due to isoforms of
the cholesterol transporter apolipoprotein (ApoE), ApoE4,
which increase risk of sporadic AD by 15 times when they are
homozygotic.5 Other genes, for example, coding for clusterin
and phosphatidylinositol-binding clathrin assembly protein,49,50
have recently been implicated by genome-wide association
studies51 and explain about half of the genetic background of
sporadic AD.52 The mechanism of their involvement is not
completely understood although they seem to be implicated in
cholesterol metabolism, immune defense, or synaptic func-
tion.52
Because the pathogenic mechanism of AD is currently not
understood, current treatments are mainly symptom-relieving
and are typically eﬀective for up to a year at best.18,53 Among
such treatments, focus has mainly been on relieving cognitive
symptoms, for example, N-methyl-D-aspartate (NMDA)
receptor antagonists (memantine) or acetylcholinesterase
inhibitors (donepezil).4,54 Given the poor therapeutic eﬀects
of current treatments, prevention has instead been suggested to
Figure 1. Simple overview of three hypotheses of Alzheimer’s disease: (i) amyloid cascade hypothesis, with Aβ accumulation (red) being a main
pathogenic event; (ii) metal ion hypothesis, with metal ion (green) dyshomeostasis leading to amyloid imbalance; and (iii) oxidative stress
hypothesis, with oxidative and general stress (blue) leading to mitochondrial damage, metal ion dyshomeostasis, apoptosis, and Aβ imbalance.
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provide better protection against AD.55,56 However, recent
developments at the interface between bioinorganic chemistry
and neuroscience have opened the door for appealing new
targets relating to zinc homeostasis, to be discussed in this
review.
Cumulated evidence shows that the risk of AD can be
reduced both by avoiding the previously mentioned exogenous
risk factors, including enhancing neuronal capacity, for example,
by education,57,58 and intake of vitamin B12, folate, antioxidants
such as vitamin E (evidence for vitamin C is not conclusive),55
unsaturated fatty acids,55,59 cereal, and ﬁsh, or controlled caloric
restriction,60 and regular mental61 and physical activity.56,57
Some factors may correlate with but not cause disease
progression: For example, education is a key component of
an active cognitive life style that may reduce risk of AD,57,58 but
education may correlate with other factors such as dietary
intake. Distinguishing correlation and causation is thus central
also to AD research.
2. AD PATHOGENESIS: THREE CURRENT COMPETING
HYPOTHESES
Since the days of the cholinergic hypothesis of AD,62,63
acetylcholinesterase inhibitors such as donepezil have domi-
nated the market for AD treatment, although this paradigm
only delays cognitive decline by typically one year.53,54 The
limited eﬃciency of these symptom-treating receptor antago-
nists has led to quests for more causative pathogenic
targets.10,64 During the past decade,4,10,16,264 three main
hypotheses on the pathogenesis of AD have emerged that
focus on diﬀerent features of the disease and are to some extent
seen as competing:10 the amyloid cascade hypothesis,4,5,65 the
metal ion hypothesis,17,66−69 and the oxidative stress
hypothesis.70−72 A crude overview of some central ideas of
these three hypotheses is given in Figure 1.
The amyloid cascade hypothesis states that impaired balance
between Aβ production and clearance is the main cause of AD
and that amyloids are the main neurotoxic substances in AD.5
Consequently, this hypothesis favors treatments that inhibit Aβ
production or enhance Aβ clearance in the AD brain.4
The metal ion hypothesis states that the underlying cause of
AD is impaired metal homeostasis, in particular of Zn, Cu, and
Fe, with Aβ imbalance being a consequence of this.67,68 This
hypothesis favors treatments such as chelators that address the
metal ion imbalances supposedly causing amyloid accumu-
lation.73
The oxidative stress hypothesis asserts that age-enhanced or
genetically and environmentally enhanced oxidative stress
results in accumulated gene defects and declining mitochon-
drial function that subsequently leads to neurological disorders,
either gradually or when reaching a critical threshold that
initiates apoptosis in neurons.70,74,75 Apoptosis occurs in a wide
range of neurological disorders and by a range of pathways that
can be triggered, for example, by lesions, misfolded proteins,
oxidative stress, excitotoxicity, or Ca2+ dyshomeostasis.76
3. AMYLOID CASCADE HYPOTHESIS
3.1. Production of Aβ
The amyloid cascade hypothesis65 focuses on the hallmark
symptom of the disease, the senile plaques, asserts that amyloid
imbalances are the main, pathogenic cause of AD, and was
primarily supported by genetic risk factors of rare familial AD
aﬀecting the production or clearance of Aβ.4,77,78 Mechanisms
of Aβ formation and clearance have been discussed in recent
reviews,8,79 and many chemical and structural aspects of
amyloids have been discussed in the review by Rauk.80
Aβ is derived from cleavage of the membrane protein APP
found both in the outer cell membrane, accessible from the
extracellular environment, and intracellularly, in membranes of
organelles such as mitochondria.8 The Aβ sequence within APP
is shown in Figure 2. There are two main pathways of APP
cleavage, the amyloidogenic and the nonamyloidogenic; both of
them occur in the normal, healthy organism, and Aβ exists in all
living persons and serves roles in the healthy brain.81
The nonamyloidogenic cleavage of APP at the α-cleavage
site, which lies within the region of formation of Aβ and
therefore precludes its later formation, is catalyzed by a group
of proteases called α-secretases and leads to formation of
innocent sAPPα peptides outside the cell.8,82,83 The α-
secretases belong to the ADAM family (a disintegrin and
metalloprotease family), for example, ADAM9, ADAM10, and
ADAM17,8 and are membrane zinc proteases.84 As an example,
a structure of ADAM17 (TACE) with a bound inhibitor is
shown in Figure 3.85 In contrast, an aspartyl protease cleaves
APP at the β-site and is referred to as β-secretase (beta-site
Figure 2. The Aβ sequence within APP and the main secretase
cleavage positions. Both Aβ numbering (Aβ#) and APP numbering
(APP#) is indicated. Amino acids are colored according to negative
charge (red), positive charge (blue), histidines (orange), and
hydrophobic (green).
Figure 3. The zinc protease ADAM17 (TACE) with α-secretase
activity (3L0T.pdb). Active-site Zn(II) (blue) coordinates three
histidines and two oxygen atoms from an inhibitor. See ref 85. Picture
made with Pymol.
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APP cleaving enzyme 1, BACE1).86,87 Subsequent cleavage by
the enzyme complex γ-secretase leads to formation of the two
variants Aβ40 (ca. 90%) and Aβ42 (ca. 10%), with 40 and 42
residues, respectively.8,10
3.2. Aβ Production−Clearance Imbalances in AD
Any disruption that aﬀects the balance between the two
pathways can alter the balance between innocent cleavage
products and Aβ: For example, low pH (β-secretase has a low
pHopt),
8 oxidative stress or hypoxia (which induces β-
secretase88−90), hypercholesterolemia (β-secretase and γ-
secretase are inhibited by reduced cholesterol levels),91 and
lack of Zn(II) in the α-secretase active sites may be
hypothesized to aﬀect Aβ production. Accumulation of
homocysteine known to occur in AD24 enhances expression
of γ-secretase in the rat brain,92 also shifting the balance toward
more Aβ.
Also, any disruption of the clearance of Aβ will lead to
amyloid accumulation, which is also of central importance.93 To
maintain a normal healthy concentration of Aβ in the brain, Aβ
is rapidly degraded by a number of proteases, including
neprilysin, insulin-degrading enzyme, angiotensin-converting
enzyme, and matrix metalloprotease-2 and -9.94,95 Thus, in the
healthy brain, the production by secretases and the clearance of
Aβ by other proteases is in balance (typically at rates of ∼8%
per hour), so that amyloids do not accumulate.96 Neprilysin is
considered the main Aβ protease97,98 that degrades both
monomers and oligomers of Aβ.99 To be discussed in this
review, it is notable that both nonamyloidogenic and Aβ-
clearing proteases depend on bound zinc in active sites, whereas
free Zn2+ ions contribute to the amyloidogenic pathway and
also stabilize Aβ against degradation.
3.3. Structural Forms and Toxicity of Amyloids
The two Aβ peptides can be found in various forms once
produced: The simple peptides react to produce (i) soluble
oligomers, (ii) protoﬁbrils, and (iii) extracellular aggregates or
ﬁbrils, which are insoluble and observed as plaques in AD.8
Both amyloids Aβ40 and Aβ42 have a total charge of −3 due to
six acidic residues, one arginine and two lysines. They contain a
hydrophobic motif that can bind to proteins and membranes
and facilitate oligomerization, while the hydrophilic part is in
solution.80 The ratio between Aβ40 and Aβ42 is important in
the formation of the soluble oligomers,100 which are considered
the toxic forms,101−103 whereas the extracellular aggregates are
not directly toxic.78 A dimeric species (weight of approximately
8 kDa) has been identiﬁed as particularly toxic.104 In vivo, there
may be dozens of Aβ species, and consideration of possible
molecular weights of these has recently been given.69 Aβ42 is
most likely more toxic than Aβ40,105 possibly because of the
two additional hydrophobic amino acids.106,107 Recently, a
number of crystal structures of interactions between amyloids
and various binders have been discussed.108
Several pathogenic mechanisms of soluble Aβ oligomers have
been given:78,109−111 (i) they may damage neurons directly
causing neuron death,112,113 possibly upon phagocytosis114 and
possibly after direct Aβ-generated oxidative insults;115 (ii) they
may destroy electrochemical signaling,116 for example, by
forming small membrane-soluble channels that impair ion
gradients, notably Ca2+,117,118 or by disrupting copper-mediated
prion-protein interaction with the NMDA receptors,119
impairing neuronal signaling and causing neuronal
death;120,121 (iii) Aβ may accumulate in mitochondria122,123
and disturb the respiratory chain, which then indirectly causes
oxidative stress (possibly via superoxide from ineﬃcient
respiration124), and neuronal death.125
New drugs are currently being developed that attempt to
prevent the formation of toxic amyloid oligomers,126 for
example, inhibitors of γ-secretase127−129 or β-secretase,130,131
control of osmolytes that have been shown to aﬀect amyloid
formation,132−134 or other types of drugs that function as α-
secretase enhancers either by inhibiting the proteases that
degrade α-secretases or by otherwise enhancing their activity or
lifetime.135 Readers are referred to the above references for
details on the pharmaceutical targeting of the Aβ production−
clearance imbalance.
4. METAL ION HYPOTHESIS
4.1. The Justiﬁcation of the Metal Ion Hypothesis
The lack of clinical success of antiamyloid drugs has led some
researchers to call for expansion or modiﬁcation of the amyloid
cascade hypothesis.65,136,137 Various anomalies, such as the
observations that neuron loss in AD is not correlated to
amyloid load,138 that 20−40% of cognitively normal people
have enough amyloid plaques to cause AD diagnosis,9 that
clinical diagnosis is necessary because Aβ biomarkers are
insuﬃcient for diagnosis,9 and that AD begins and Aβ
accumulates in the hippocampus and cerebral cortex, although
Aβ itself is generated throughout the brain,73 indicate that the
pathogenesis of the amyloid cascade is poorly understood.73
Furthermore, a toxic mode of Aβ, while several are known and
suggested, has not been found to be causative of AD. Even if
apo-Aβ oligomers in principle remain plausible key toxic
substances in AD pathogenesis, the underlying causes for
impaired Aβ balance, which is now known to be substantially
controlled by metal ions both at the APP and Aβ processing
levels,17,139 must clearly be addressed.10,25,73
The metal ion hypothesis11,73 was inspired by early
suggestions140 and later observations10,95,141−143 that AD
correlated with dyshomeostasis of metal ions, notably ﬁrst Fe,
and later Zn and Cu.10,144,145 Iron levels have been reported to
be higher in AD neuropils vs healthy neuropils146−148 (the
region between neurons where synaptic connections form), and
iron is abnormally concentrated (millimolar concentrations) in
amyloid plaques.148 Magnetic resonance imaging can be
used149,150 to show that upon cerebral amyloid angiopathy, a
lesion commonly associated with AD, the nonheme iron pool
(i.e., free Fe3+/2+) is increased. Furthermore, Cu levels are
generally reported to be depressed in AD brain tissue.69,151−153
Currently, several genetic risk factors have also been connected
to metal ion homeostasis, notably presenilin linked to calcium
homeostasis and recently also to copper and zinc transport,154
and mutants of the recently identiﬁed Picalm gene,49−52 coding
for phosphatidylinositol-binding clathrin assembly protein, are
known to cause iron homeostatic deﬁciencies in mice.155 Also,
it is now clear that the central protein in the amyloid cascade,
APP, is in fact regulated by and reacting with metal ions that
aﬀect amyloid balance, as will be discussed in detail below.
While discussing the metal ions, a distinction between two
pools of metal ions will be made, namely “free” (i.e., loosely
bound), often solvent-exposed, and mainly chelatable M2+/M3+
vs strongly bound M(II)/M(III) in proteins. As will be clear
later, this distinction is suggested to be crucial for under-
standing the pathogenesis of AD. To render the distinction
semiquantitative, an approximate threshold for the dissociation
constants, Kd ≈ 10−7 M, will be used. The bound pool of M(II)
Chemical Reviews Review
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thus refers to metal ions bound to peptides and proteins with a
Kd < 10
−7 M, common for buried, speciﬁc metal-binding sites in
peptides and proteins, whereas the free pool implies Kd > 10
−7
M, which is common for metal ions binding solvent-exposed
amino acid residues on surfaces of proteins.156
While much focus has been on the homeostasis of
Cu17,157,158 and Fe159−161 in AD,162,163 recent attention has
been directed toward Zn in AD,10,25,164 which is the center of
focus of this review. Zinc content has been reported to be
abnormally high in blood165 and hippocampus166 of AD
patients. However, in the cerebrospinal ﬂuid, zinc levels seem to
be lowered in AD patients,167 and globally in the brain, zinc
levels have been reported to be unchanged152 or reduced168,169
in AD. Thus, zinc levels in AD are debatable,170 and there is
substantial heterogeneity in the reported zinc levels,152 possibly
due to sample heterogeneity, variable attention to free,
chelatable Zn2+ vs protein-bound Zn(II) pools, and redis-
tributions within the brain as a function of disease progression
and age. Thus, in the neocortex, the outer layer of the cerebral
cortex sheet that covers the brain and is involved in learning
and memory, there is disagreement between reports, some
concluding that all metal ion levels including zinc are
elevated171 and some reporting no signiﬁcant changes in
overall zinc levels.152 However, there is consensus that zinc is
abnormally distributed in AD patients, with more zinc retained
inside tissue and neurons, in particular in the synaptic
vesicles,10,170 and more zinc retained in amyloid plaques,
consistent with elevated expression of neuronal Zn transporters
(ZnT) ZnT4 and ZnT6 in early AD.10,172−174 In a recent meta
analysis, both iron and zinc were found to be more
concentrated in certain parts of the brain such as the
putamen,152 which is strongly reduced in size in AD.175
A critical breakthrough for the metal ion hypothesis came
from multiple independent observations that Zn(II) and Cu(II)
are essential for formation and structural integrity of amyloid
aggregates, oligomers, and ﬁbrils,176−184 as reviewed re-
cently,185 while normal physiological metal ion concentrations
are not high enough to induce aggregation.186 Furthermore,
morphological evidence shows that ZnTs are necessary for
plaque formation:187−189 The Zn(II)-amyloids themselves are
usually thought to be nontoxic, whereas Cu(II)-amyloids are
neurotoxic,190 although it has been reported that addition of
free (i.e., in salt form) Zn2+ to Aβ stabilizes intermediates that
lead to toxic oligomers on millisecond time scales, that is, Zn2+
may take part in the formation of the toxic oligomers.191
Structural interactions of both copper and zinc with amyloids
have been described in great detail.176,178−183,192−194 It is now
accepted that amyloidosis is not spontaneous but requires metal
ions for initiation.181,195 These ﬁndings have been accompanied
by similar discoveries of the roles of metal ions in protein
misfolding, for example, relating to Parkinson’s disease.196−198
4.2. Coordination Structures of Aβ−Metal Complexes
The structures of Zn(II)−Aβ192,199,200 and Cu(II)−Aβ201 have
been investigated in great detail by NMR,200,202,203 X-ray
absorption spectroscopy,204,205 and Fourier transform infrared
spectroscopy.192,206 Both Cu(II) and Zn(II) are borderline
hard−soft Lewis acids, with aﬃnity toward N, S, and O ligands.
In the free Cu2+ and Zn2+ forms, both ions will have a typical
coordination number of 6, either fully hydrated as hexaqua ions
or loosely bound on the surface of proteins, several with typical
Kd > 10
−6 M. In the bound Cu(II) and Zn(II) forms on protein
active sites or speciﬁc regulatory sites, Kd's can be much smaller
(vide inf ra) and coordination numbers may often be smaller
than 6, due to the strain imposed by the peptide backbone, the
entropy release due to the chelate eﬀect on binding a peptide
chain, and the basicity of involved amino acid ligands.
Most signiﬁcantly, electron paramagnetic resonance (EPR)
studies have been useful in elucidating the structures of
paramagnetic d9 Cu(II)−Aβ,185,207−209 in particular when using
site-speciﬁc isotopic labeling to deduce coordination modes as
previously done with prion protein.210 Given the dynamic
structural interconversions of the Jahn−Teller distorted d9
metal ion Cu(II) in water,211 dynamic coordination geometries
in Cu(II)-amyloids causing several types of reported coordina-
tion modes185,212 are understandable, and Cu(II) geometries
will thus be tetragonally distorted octahedral (coordination
number 6) or trigonal bipyramidal (coordination number 5).
Cu(II) normally binds Aβ in a 1:1 stoichiometry,213 possibly
with the existence of a second, low-aﬃnity binding site,214 and
the second site may be destroyed by steric crowding in Aβ42
but be intact in shorter peptides.215 The dominating binding
site, located at residues 1−16,216 changes with pH. At
physiological pH, ∼6−7, component I dominates,183,217
whereas at higher pH, component II dominates.185,218
Furthermore, the physiologically important component I of
Cu(II)−Aβ consists of at least two species in equilibrium,
components Ia and Ib,208 and possibly a minor third
component.219 The current view from labeled EPR studies is
that these two components consist of four- or possibly ﬁve-
coordinated Cu(II) with two imidazole nitrogens (His-6 and
His-13/14 in component Ia/Ib),207,208,220,221 one N-terminal
amine nitrogen from Asp-1,218,222 and the carbonyl oxygen of
Ala-2,185 possibly with a ﬁfth, weakly bound apical/axial
carboxylate from the side chain of Asp-1,192,209 in contrast to
previously assigned full coordination of carboxylate oxy-
gen.201,209 The consensus structure is shown in Figure 4.
Also, Arg-5 may be involved in some coordination modes,185
and solvent-exposed coordination modes may occur at higher
Cu(II) concentrations.223 For the apparently less physiologi-
cally relevant component II, several structures have been
proposed, and consensus has not yet been reached.185,207,222
In contrast, the symmetric, closed-shell d10 metal ion Zn(II)
binds with less structural variation for histidines and still to the
same hydrophilic metal-binding 1−16 fragment of Aβ, with 1:1
stoichiometry.182 For solvent-exposed Zn(II), a coordination
Figure 4. The currently most plausible ﬁrst-coordination sphere
structure of Cu(II)−Aβ at physiological pH. Component Ia implies
coordination of His-13, and component Ib implies coordination of
His-14. See text for details.
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number of six is expected, whereas in peptides and proteins,
coordination numbers may be smaller as solvent exposure is
reduced, that is, four or ﬁve. Whereas transition metal ions
sacriﬁce ligand ﬁeld stabilization energy upon lowering the
coordination number in peptides, Zn(II) does not suﬀer this
penalty because it is d10. In Aβ, Zn(II) is found to bind to
nitrogens of His-6, His-13, and His-14 without varia-
tion.199,200,224−227 The remaining ﬁrst coordination sphere
depends on conditions. A tetrahedral geometry is possible with
one additional monodentate ligand; a trigonal bipyramidal
geometry is obtained when a bidentate carboxylate, such as
Glu-11 (see Figure 5),200 or two more monodentate ligands
bind; and a octahedral geometry occurs if three additional
ligands including solvent water bind.228 Several Aβ ligands have
been implied in binding Zn(II) in addition to the three
histidine residues, the Asp-1 N-terminal amine,200,224,225 the
Glu-11 carboxylate side chain,199,200,228 and the deprotonated
amide of the Arg-5 backbone. Also, Tyr-10 could possibly be
involved in some Zn(II) binding modes.200 This would be
particular interesting in Cu(I/II) mediated redox toxicity,
where tyrosine could play a role as a radical as in several copper
enzymes229 but is generally absent in the monomer Cu(II)
structures under studied conditions, as explained above, and
probably also in Zn(II)−Aβ under normal conditions.230
4.3. Coordination Structures of Aβ Sequence Variations
Of substantial interest are structure−function correlations
obtained from sequence modiﬁcations of Aβ. A main diﬀerence
between rat models of AD and human AD is the lack of His-13
and Arg-5 in the rat Aβ metal-binding sequence. His-13 binds
to both Cu(II) in component Ia and to Zn(II) in Zn(II)−Aβ.
The absence of this residue in rat amyloids reduces the metal
ion aﬃnity and leads to absence of amyloid deposits.68 His-13
is, together with His-14, a target of reactive oxygen species
(ROS) production in Cu(II)-amyloids,231 and is essential for
Zn2+-induced amyloid aggregation.232
Sequence modiﬁcations of human Aβ are also important for
elucidating the binding modes of the metal−Aβ complexes.
While the majority of AD cases are sporadic and imply a
systemic, multifactor etiology, some cases are familial.233
Among these are mutations in APP and presenilin that can
aﬀect the amyloid balance by changing the ratio between β- and
α-secretase turnover, for example, by reducing α-secretase
binding to the α-cleavage site, or changing the Aβ42/Aβ40
ratio,234 but there are also mutations present in the actual Aβ
sequence range that cause familial AD and aﬀect the chemical
properties of the produced amyloids, notably enhanced
ﬁbrillation from mutation at positions 22 and 23 such as the
Dutch (E22Q), Italian (E22K), Arctic (E22G), and Iowa
(D23N)235 mutations that all tend to increase amyloid charge.
One mutation found to work to both eﬀects is the APP
A673V mutation that may cause AD when the mutation is
homozygotic, that is, present in both APP allelles.236 This APP
mutation occurs in the amyloid region, at position 2 (A2V in
Aβ). EPR and hyperﬁne sublevel correlation (HYSCORE)
spectroscopy can contribute to understanding the structural
features of modiﬁed Cu(II)−Aβ that enhance stabilization or
toxicity.237 While the ﬁrst coordination sphere was found to be
unaﬀected, there was a signiﬁcant (∼0.5) change in pKa of Aβ
due to the A2V mutation.237 This is important because the
metal binding changes with the pH (vide inf ra) and thus with
the charge state of titratable ligands, which may provide a clue
to the enhanced toxicity of the mutation.
Two other mutations of APP that occur in the Aβ region are
the dominant “English” H6R and “Tottori” D7N mutations,
associated with aggravated oligomer ﬁbril formation toxicity.234
These mutations, which like most others mentioned above
increase amyloid charge, which could aﬀect hydrophobicity,
solubility, and metal-binding properties, display altered
structure and Cu(II) binding and a disturbed ratio between
components I and II, as evident from a range of spectroscopic
methods.238 Such bioinorganic chemical insight may help to
explain the toxicity of Aβ mutants, and ultimately explain the
pathogenesis of genetic risk factors.
Whereas apo-amyloids are negatively charged at physiological
pH,239 metal−Aβ complexes will change the charge distribu-
tion, depending on the coordination mode and exact pH,
plausibly increasing their hydrophobicity, permeability, and
aggregation properties as seen for Zn(II),240 which are critical
to Aβ−membrane interactions.239 It is in this respect notable
that all the charge-increasing mutations are dominant, whereas
the A2V mutant is recessive and displays diﬀerent morpho-
logical and structural plaques with distinctly diﬀerent
distributions in the brain.241 The neutralizing (increased
hydrophobicity) tendency of many pathogenic mutations in
the Aβ sequence of APP could be a key to understanding the
pathogenesis of the produced amyloids in AD, if secretase
modulation at the actual APP is not the main cause (this could
be due to charge neutralization reducing, for example, α-
secretase kcat/KM). Notably, a recent mutation (D7H) causing
early onset AD also shares the neutralizing criterium and
additionally displays enhanced metal binding properties.242
Together with the altered coordination modes of familial
AD-causing Aβ-mutations, the diﬀerent coordination modes of
Zn(II) and Cu(II) in human Aβ could explain the diﬀerent
rates of their amyloid formation,243 as could the diﬀerent
kinetics observed for Cu(II)-induced Aβ formation in rats and
humans.244 Also, K-edge X-ray absorption spectroscopy
suggests that the coordination mode of Cu(II) diﬀers in Aβ
monomers and the assumed toxic oligomers,245 an important
focus to completely understand the structure−function
correlations leading to metal-induced oligomerization and
possibly toxicity. Furthermore, recent spectroscopic studies246
on mixed Zn(II)/Cu(II)−Aβ complexes conclude that Zn(II)
Figure 5. The Zn(II)-binding motif of Aβ, 1ZE9.pdb. Published in ref
199. Picture produced using Pymol.
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can disturb the Cu(II) coordination mode away from histidine-
binding and thus possibly protect against a toxic Cu(II)-binding
mode. Given the stronger Cu(II) binding, such a displacement
is surprising, although not impossible when only some ligands
are involved in the substitution. In fact, this mechanism may
resemble the proposed beneﬁcial substitution of Cu(II) for
Zn(II) in Cu(II)−Aβ by Zn7-metallothionein,
247 to be
discussed later. More molecular insight into the interplay
between Zn(II) and Cu(II) in amyloid binding and
oligomerization is clearly warranted.
4.4. The Aﬃnities of Metal Ions for Aβ
A central focus of bioinorganic AD research is to systematically
understand the aﬃnities of metal ions for various targets
associated with the disease, most often described by the metal
dissociation constant, Kd. Kd's are essential for the concept of
free and bound metal ion pools, which may be critical to AD
pathogenesis (vide supra), and to deﬁne potent chelation and
metalloprotein inhibition therapies. The determination of
accurate Kd's by competitive ligation is quite challenging and
results diﬀer greatly depending on pH and ionic strength,
unintended formation of ternary or buﬀer complexes, or
ineﬃcient competition.156
Thus, the reported stabilities of 1:1 metal−Aβ complexes
vary substantially,212,248,249 with reported conditional Kd's in
the range from 10−11 to 10−7 M for Cu(II)−Aβ (most likely
consensus 10−10 to 10−9 M156,249) and 10−9 to 10−6 M for
Zn(II)−Aβ, with Kd values of ∼10−7 M being seen in most
studies,192,212 although very weak Kd's ≈ 10−6 to 10−5 M have
also been inferred.228 Cu(II) typically binds 2 orders of
magnitude better than Zn(II) in these histidine-binding
systems. The Irving−Williams series of increasing stability
constants puts Cu(II) before Zn(II) due to its strong Jahn−
Teller eﬀect,250 as also seen for oxygen ligands such as EDTA
with typical Kd's of 10
−19 and 10−17 M for Cu(II) and Zn(II),
respectively.251 For many nitrogen chelators, 105−106 orders of
magnitude diﬀerence between Cu(II) and Zn(II) is common
for overall association constants, whereas for peptides and
proteins discussed in this review, 2 orders of magnitude
diﬀerence between Cu(II) and Zn(II) is more common.
For comparison, typical concentrations of copper and zinc in
AD senile plaques are ∼0.4 and ∼1 mM, respectively,148 similar
in ﬁbrils and soluble oligomers.192 Recently, a kinetic three-step
mechanism of Cu(II)-induced oligomerization was suggested
based on ﬂuorescence and NMR spectroscopy, identifying a
nonoligomeric, that is, potentially innocent, monocopper−
diamyloid complex that may be targeted for preferential
stabilization as a treatment strategy.195
In addition to copper and zinc, also other free metal ions
such as iron or aluminum252 may interact with, stabilize, or
induce aggregation or oligomer formation of Aβ.253 On a
parallel note, heme-iron homeostasis has been found to be
impaired in AD,254 and heme binds to Aβ and inhibits both
aggregation and oxidative toxicity of Aβ in vivo.255,256 Given the
importance of heme homeostasis for the mitochondrial
neuronal energy production and antioxidant activity, this is a
signiﬁcant observation that may further link metabolic
deﬁciencies in AD to the metal ion hypothesis.255,257 The
same metal binding region 1−16 of Aβ as involved in Cu(II)
and Zn(II) binding also binds to heme. Most likely, heme binds
mainly to His-13 or possibly His-14 via axial coordination to
heme.258 In principle, up to two histidines can coordinate at a
time to generate a coordination number of 6 as in octahedral
coordination geometries of cytochromes, for example, but EPR
data indicate a g value of ∼6 resembling high-spin as in
pentacoordinate deoxyheme.258 Interestingly, heme may out-
compete Zn(II) or Cu(II) in amyloids, thus preventing
oligomer formation.254 As implied by other diﬀerences between
rat and human Aβ structures diﬀering in metal-mediated
aggregation and toxicity, heme also binds diﬀerently to human
and rodent amyloids and could indicate a heme−Aβ-mediated
mode of oxidative toxicity in AD.259
4.5. The Role of Zinc in AD
Zinc plays a central role in the central nervous system (CNS) in
processes such as apoptosis, oxidative stress, and immune
defense,260 neurogenesis, motor coordination, memory, and
synaptic plasticity.261−263 Zinc dyshomeostasis is a pathological
feature of AD,264−267 depression,264,268,269 Parkinson’s dis-
ease,267,270 autism spectrum disorders (ASD),271,272 amyotro-
phic lateral sclerosis (ALS),267,273,274 epilepsy,275,276 and
schizophrenia.264
Zn(II) is bound in more than 300 proteins,277 in tran-
scription zinc-ﬁngers (typical Kd's ≈ 10−12 M278 although down
to 10−15 M has been observed279), stored in metallothioneins
(MT), and present as a free, chelatable Zn2+ pool in the vesicles
of terminals of zinc-enriched neurons (ZEN), for example, zinc-
and glutamate-releasing (gluzinergic) neurons.280 The gradient
of the free Zn2+ pool is tightly controlled with only 10−12 M
free intracellular Zn2+ and up to millimolar vesicular Zn2+144 by
MTs for storage and buﬀering and by transportation across
membranes via zinc transporter proteins of two families, ZnT
and ZIP.281 Once in the vesicles of neurons, the vesicular Zn2+
is released during neurotransmission together with glutamate
and modulates glutamate-activated neurotransmission via
inhibition of γ-aminobutyric acid (GABA) and NMDA
receptors10,262,264,282,283 by binding speciﬁc Zn2+-binding sites
in the receptors.284 The gluzinergic neurons are mainly located
in the cerebral cortex, the central stage of AD, and in particular
in the limbic system.264,285
The role of zinc in AD pathogenesis, ﬁrst suggested by
Burnet,264 is substantiated by observations that the genetic risk
factor in familial AD, the ε4 apolipoprotein E gene, is correlated
with higher serum levels of Zn, Cu, and insulin, and that only
zinc is an independent risk factor, not ε4 apolipoprotein E
itself.286 Zinc-dependent amyloidosis can also explain some
gender diﬀerences in plaque formation in APP transgenic
mice,287 although many other factors aﬀect gender-speciﬁc risk
factors of AD, for example, life style, genetic, and cholesterol
correlations. However, evidence of zinc dyshomeostasis in AD
comes from the vast number of reports describing changes in
ZnT levels, zinc redistribution, and direct zinc-amyloid
interactions, as described in sections 4.1 and 4.2.
Zinc aﬀects Aβ balance in several ways, both via transcription
factor zinc-ﬁngers, in regulatory Zn2+ sites notably in APP, and
as bound Zn(II) in active sites of zinc proteases.10 First,
regulatory Zn2+ can directly bind and inhibit APP at the α-
secretase site,288 leaving APP to cleavage by the other two
secretases to enhance production of Aβ.67 Other researchers
have observed reduced total Aβ production but enhanced
intracellular Aβ production upon zinc binding to APP.289 The
zinc-binding site in APP has a conditional Kd of ∼10−6 M,
288
similar to or slightly weaker than that of Zn(II)−Aβ. The
central AD protein APP, long obscure in its biological role, has
recently been found to possess ferroxidase activity, oxidizing
Fe2+ to Fe3+ before loading Fe3+ into transferrin, and this
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function is inhibited by Zn2+.290 This mechanism could provide
a coupling between iron dyshomeostasis and Aβ imbalance and
would make zinc dyshomeostasis a plausible cause of both.
In addition to the copper binding domain in the E1
extracellular domain of APP, to be discussed below, several
metal sites in the extracellular E2 domain of APP have recently
been structurally characterized by X-ray diﬀraction, providing
evidence for Cu(II) and Zn(II) as controlling regulatory metal
ions in the conformation and possibly function of this
domain.139 Two intramolecular metal binding sites and several
solvent-exposed sites were observed, with the high-aﬃnity M1
site consisting of four histidines (APP sequence numbers His-
313, His-382, His-432, and His-436) binding to Cu(II) in a
Jahn−Teller distorted square planar geometry. In case of
Zn(II), His-313 is substituted for a water ligand (see Figure 6).
In the Cu(II) form, two α helices are bridged by the metal ion,
whereas in the Zn(II) form, since His-313 is located on a
separate α helix, there is no direct bridge. The Kd's for the site
were found to be ∼10−8 and ∼4 × 10−6 M for Cu(II) and
Zn(II), respectively, in good agreement with previously
determined values.287
Zn(II) is also required in the active site of the ADAM family
of α-secretases to catalyze the nonamyloidogenic cleavage, as
shown in Figure 3.8,291 Furthermore, free Zn2+ also inhibits
matrix metalloprotease-2, neprilysin, and insulin-degrading
enzyme (see Figure 7),292 which degrade Aβ.94 The
extracellular metalloproteinases are expressed in the astrocytes,
to be discussed further below.94
Regarding neurotransmission and cognition, free Zn2+ is
known to inhibit GABA receptors,10,293 thus modulating their
Cl−-mediated hyperpolarization, facilitating controlled neuro-
transmission and preventing excitotoxicity.10 It is the Zn
transporter ZnT3 that loads Zn2+ into the synaptic vesicles
where it is again released during neuromodulation.68 This is the
likely reason excessive free Zn2+ causes seizures and may be a
trigger of epilepsy.294−296 Mice without ZnT3 still accumulate
free neurotoxic Zn2+ from intracellular stores not associated
with the synaptic vesicles, where the ZnT3 is located, indicating
a key role of intracellular zinc buﬀering proteins, that is,
metallothioneins, in neurodegenerative zinc dyshomeostasis.297
Excess free Zn2+ will ultimately lead to neuronal necrosis or
apoptosis.10,264,298−300 Excess free Zn2+ also induces phosphor-
ylation of tau-protein301 and remains located in neurites with
neuroﬁbrillar tangles.302
4.6. The Role of Copper in AD
Copper homeostasis is of vital signiﬁcance to the brain303,304
and is also impaired in AD as in other neurological
disorders.305−308 Copper homeostasis is extremely critical,
because concentrations of free Cu2+ beyond 10−18 M may
cause oxidative damage.309 The most common transported
form of copper is instead Cu(I).310 Copper in both oxidation
states is located in active sites of a number of vital redox-active
proteins such as ceruloplasmin, cytochrome c oxidase, prion
protein, tyrosinase, and Cu,Zn-superoxide dismutase (cytoplas-
mic SOD-1 and extracellular SOD-3), and its absence from
these proteins is dramatic, as seen from neuronal degeneration
in Menkes disease caused by lack of copper transport across the
blood−brain barrier (BBB).304
While total Cu levels are mostly observed to be depressed in
AD,152,153 some reports show increased levels148,253 and some
reduced levels in AD brains (hippocampus/amygdala),311
probably reﬂecting the loss of bound pools, subsequent
redistribution to extracellular space,69,312 speciﬁcally to Aβ in
the cerebrospinal ﬂuid313 and eventually to the blood serum.314
Thus, the emerging consensus of copper seems consistent with
that of zinc, namely, relocation from intracellular to
extracellular stores and from bound to free pools present in
Figure 6. M1 binding site in the amyloid precursor protein (APP)
extracellular E2 domain, occupied by Zn(II). PDB code 3UMI. Picture
produced with Pymol.
Figure 7. Zn2+-binding site in the human amyloid-degrading protease, insulin-degrading enzyme. PDB-code 2G54.pdb. From ref 292. Picture made
with Pymol.
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serum or in Aβ deposits, as seen in mouse models of AD,315
although total Cu levels are also generally depressed.152,153 This
picture of temporal and spatial changes in the two pools is
important for the design of proper biomarkers and for
discussing metal ion levels in neurological disease, including
AD.
The uptake, storage, transport, and transfer of Cu(I/II) to
proteins depend on a range of copper transporters and
chaperones.316 After being mostly absorbed in the liver, it is
incorporated into copper proteins (notably ceruloplasmin
discussed in section 4.8) by chaperones. To reach the brain,
copper is transported ﬁrst across the BBB via copper pumps
(copper ATPases ATP7A and ATP7B)317,318 with the possible
help of Atox1, which may work as a Cu(I) chaperone for
ATP7A319 and has been reported to facilitate antioxidant
function in neurons320 and cell growth.321 Subsequently,
copper is taken up by the copper transport protein
Ctr1322−324 and distributed to its various destinations in the
neurons, notably in the plasma membrane and in vesicles.310
Ctr1 and the copper ATPases are regulated by the copper
concentration, and copper binding in regulatory sites promotes
endocytosis and degradation of Ctr1 to prevent further copper
uptake and intraneuronal copper accumulation.310,325
Copper binds to prion protein and ceruloplasmin (90% of all
blood Cu144), and a signiﬁcant part is kept in the brain in
MTs,305,326,327 particularly inside the astrocytes, mainly in the
Cu(I) form.316 Some of this Cu(I) from MT has been shown to
be transferred to SOD in vitro, although not in vivo,327 and Cu-
containing MT-3 is likely to act as a Cu-transferring chaperone
for several Cu proteins.328,329 Various other chaperones transfer
copper to critical proteins such as antioxidant SOD (copper-
chaperone for superoxide dismutase, CCS)309,330 and respira-
tory cytochrome c oxidase (Cox17).331,332 Mutations or post-
translational modiﬁcations in these proteins could in principle
impair copper homeostasis in the brain causing sporadic risk of
neurological disease, CCS for ALS and Cox17 for mitochon-
drial impairment seen in most neurological disorders.
The loss of protein-bound Cu(II)/Cu(I) probably reﬂects
reduced function of copper proteins, but whether this loss is a
cause or eﬀect of neuron degeneration (e.g., following
apoptotic events) must be investigated. For example, recent
work suggests a new toxic mode of Aβ via interference with
copper/prion-protein modulation of NMDA receptors that
would interrupt Ca2+-dependent neurotransmission.119 Dis-
rupted copper active sites are a smoking gun in neuro-
degeneration, because they lead to neurological disorders such
as ALS (Cu,Zn-SOD-1 by gain of toxic function333),
Parkinson’s disease (α-synuclein),90,91 or Menkes and Wilson
disease (copper ATPases ATP7A and ATP7B, respec-
tively)305,306 and may further explain impaired mitochondrial
energy production (i.e., low glucose uptake in brain disorders),
for example, via Cu- and Fe-containing cytochrome c oxidase.
Cytochrome c oxidase is also known to be inhibited by free
Zn2+,334,335 providing an example where metal dyshomeostasis
may converge to impair mitochondrial energy production.
In addition to loss of bound Cu(I)/Cu(II), several
pathogenic mechanisms of free Cu+/Cu2+ are known:336 Cu2+
may bind to APP, possibly at a site involving His-147, His-151,
and Tyr168,337 and initiate oxidative stress via reduction to Cu+
and subsequent formation of hydroxyl radicals.338 The Cu(II)
binding site in APP has a Kd of ∼10−8 M,
339 which is reasonable
given that the Zn(II) binding site has an estimated Kd ≈ 10−7
M.288 Intracellular reductions in Cu availability, as observed in
AD,69,151,153 lead to enhanced production of Aβ, providing one
more cause of amyloid imbalance,340 and regulation of APP via
this site is a possible mode for this.
In addition to post-translational modiﬁcation of APP, Cu(II)-
Aβ also produces ROS by itself, for example, peroxide
formation341 and lipid peroxidation initiated by Cu(II)-induced
dityrosine formation from Tyr-10.342 It is important in this
context that Cu−Aβ is more toxic than apo-Aβ,341,343,344 and
Cu(II) may confer toxicity to the Aβ in a concentration-
dependent manner.345,346
Aβ oligomers may enhance permeability of neuron and
organelle membrane where APP is located and cause
membrane dysfunction disrupting homeostasis.347 γ-Secretase
has been found in the mitochondrial membranes348 and
intracellular Aβ8 produced in this way could penetrate the
mitochondrial barrier from the cytoplasm in synaptic terminals
where APP and amyloids are enriched.347 Amyloids can also
accumulate inside the mitochondria as seen in APP-over-
expressing mice.123,349 Inside the mitochondria, amyloids
disturb normal mitochondrial functions in a variety of ways
leading to Ca2+ dyshomeostasis and apoptosis.350
Whether the membrane toxicity of amyloid oligomers is the
critical toxicity in AD and, if so, whether it involves or even
requires metal−Aβ complexation in the toxic form is unknown,
and such information could potentially help to reconcile the
amyloid-cascade and metal-ion hypotheses. However, the two
hypotheses are also consistent absent a toxic metal−Aβ mode
given that metal ions remain necessary for induction of toxic
oligomer formation and APP regulation. Still, given the role
played of hydrophobicity in membrane interactions of
amyloids,239 a membrane-toxic mode of metal-oligomers is
plausible given the likely enhancement of hydrophobicity
caused by partial charge neutralization of the negatively charged
Aβ upon metal binding, which could render amyloid oligomers
less amphiphilic membrane-binding and more membrane-
penetrating. Supporting the role of hydrophobicity as a toxic
property (by oligomerization propensity or membrane
permeability), many familial AD mutations are charge-
neutralizing as discussed in section 4.3, and the Aβ42 contains
two more hydrophobic residues at the C-terminal (Figure 2). In
contrast, the apo-amyloids could in fact function as antioxidants
during normal metal homeostasis.80,336
4.7. The Role of Calcium in AD
In this review, divalent calcium is written exclusively as Ca2+
instead of Ca(II) to mark it as a mainly free, often hydrated and
labile, redox-inactive metal ion with dissociation constants
ranging between 10−9 and 10−4 M,351 but typically in the
micromolar range as seen for calmodulin.352,353
In the healthy cell, the cytosolic concentration of Ca2+ is
maintained close to 100 nM, 4 orders of magnitude lower than
extracellular concentrations (∼2 mM), due to Ca2+ storage
proteins such as calbindin and by active transport via Ca2+-
ATPases.354,355 Disturbance of this homeostasis will aﬀect
mitochondria that utilize Ca2+ in energy production, speciﬁcally
enzymes such as pyruvate dehydrogenase, isocitrate dehydro-
genase, and ATP synthase, which are all regulated by Ca2+.355 If
Ca2+ concentration is abnormally high inside mitochondria, it
becomes a main cause of neurotoxicity.356 Glutamatergic
neurons with impaired mitochondria produce too little ATP
and may not be able to retain the membrane potential needed
to allocate Mg2+ to NMDA receptors, leaving them chronically
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open to Ca2+ and causing excitotoxicity, mitochondrial
membrane permeability, and apoptosis.70,357
The involvement of calcium dyshomeostasis in AD has been
known for more than 2 decades358 and has been reviewed
recently by several authors.359−363 Age-correlated gene
expression related to calcium homeostasis has been shown to
be magniﬁed in AD.364 The role of calcium dyshomeostasis in
AD has been emphasized via mutants in presenilin, a key risk
factor in AD and part of the γ-secretase complex,365,366 and
increased intraneuronal [Ca2+] is correlated with APP
mutations, ApoE4 expression, tau hyperphosphorylation, and
Aβ-plaque formation.117,367 Recent genetic risk of AD was
further associated with the calcium homeostasis modulator 1,
conﬁrming this relationship.368,369 The possible roles of
presenilin in calcium transport and homeostasis have recently
been reviewed.367,370 Notably, presenilin appears to function as
a calcium leak channel independently of the activity of the
enzyme complex γ-secretase of which presenilin is also a
part.370
Impaired calcium homeostasis provides the simplest possible
explanation (in the Occam’s Razor sense) of reduced synaptic
plasticity and memory deﬁcits in AD,371 where other
hypotheses must identify new modes of impaired memory
formation and maintenance. Furthermore, apoptosis, one of the
programmed cell death processes that terminate many
neurological diseases including AD, depends directly on
calcium homeostasis. Caspases that mediate apoptosis are
Ca2+ dependent and are found to be activated in aging people
and more so in AD.76,372 Calcium dyshomeostasis is further
aggravated by Aβ, which may increase Ca2+ permeability.373
This may be a primary toxicity of Aβ and would imply that
calcium dyshomeostasis is a consequence of previous Aβ
imbalances.117,120,374
Many of the pathogenic aspects of calcium correlate with and
perpetuate those of zinc due to the interplay between these two
metal ions in glutamate-controlled neurotransmission354 and in
membrane transport;375 for example, Zn2+ transport to
mitochondria mainly occurs via the Ca2+ uniporter.144 Also,
as mentioned above,119 Aβ may disrupt Cu−prion-protein
mediated NMDA receptors involved in Ca2+ signaling, linking
the calcium dyshomeostasis and neurotoxicity observed in AD
directly to zinc, copper, and Aβ.
4.8. The Role of Iron in AD
Iron homeostasis is critical to the CNS, as evidenced from iron
dyshomeostasis observed in neurodegeneration.376−383 Iron is
as mentioned also dysregulated in AD14,15,159,160,384 with
abnormally distributed iron pools in AD,385 notably an
increased pool of free, nonheme iron Fe3+/Fe2+ and functional
heme deﬁciency.151,386 In fact, heme degradation has been
suggested as a biomarker for early detection of AD387 and
dysregulated free iron pools have been suggested as a main
cause of several neurological disorders.377 Section 4.2 described
the speciﬁc interactions between heme and amyloids that could
be a consequence of this dysregulation. Also, transferrin levels
have been found to be depressed in AD.388
Iron homeostasis is normally governed by a range of proteins
such as ferritin and transferrin,389 which store ∼25% of the
body’s iron, mainly as ferric Fe3+, and have been implicated in
neurodegeneration,390 and by the heme-pool, that is, mainly
ferrous iron bound to heme proteins such as hemoglobin and
myoglobin, which store more than half of the total iron,391 the
heme carrier protein 1,392 and the heme-degrading enzyme
heme oxygenase (HO), which is also implicated in AD.393,394
The peptide hormone hepcidin plays a key role in iron
regulation159 and regulates, for example, divalent metal
transporter 1 (DMT-1), which plays a signiﬁcant role in
transporting not just iron but also copper395 and has been
implied in Parkinson’s disease396 and as a transporter of the
metal ions that regulate the processing of APP and thus
amyloid production.397 Neurons express transferrin and DMT-
1 but generally little ferritin, suggesting that the iron pool of
free Fe3+/Fe2+ is tightly controlled, and that iron is immediately
recruited by neurons when required.383 This recruitment
requires reduction of Fe3+ to Fe2+ before binding to DMT-1.383
Iron is responsible for O2-storage in hemoglobin and
myoglobin and is necessary for mitochondrial O2-dependent
energy production via a large number of enzymes, for example,
NADH dehydrogenase (complex 1), cytochrome bc1 (complex
3), and cytochrome c oxidase (complex 4) in the mitochondrial
electron transport chain. Thus, impaired Fe/heme metabolism
may play a role in metabolic deﬁciencies observed during AD
pathogenesis.259 Iron is also in the active sites of several
enzymes involved in synthesis of neurotransmitters, for
example, tryptophan hydroxylase catalyzing the ﬁrst step of
serotonin and melatonin synthesis.398
Iron accumulates in the aging brain and enhances the overall
oxidative stress level.399 Heme dyshomeostasis is evident in AD
from the interaction of heme oxygenase with neuroﬁbrillar
tangles,400 reactive astrocytes, and senile plaques in AD brain
tissue401 and from reduced activity of heme oxygenase in the
Swedish AD-causing APP mutants related to mutant APP
disrupting heme oxygenase activity.402 In AD, iron-caused ROS
production is evident.403,404 Toxic concentrations of iron are
found in extracellular Aβ of AD patients,147,381 testifying to its
role in plaque formation as a possible consequence of elevated
free iron concentrations.178 In AD hippocampus and cerebral
cortex, this dysregulation is partly compensated by elevated
levels of iron storage proteins.405
In terms of toxic mechanism, free Fe3+ and Al3+ have been
found to induce tau protein aggregation, whereas divalent metal
ions did not.406 Overexpression of heme oxygenase causes tau
phosphorylation and aggregation in mouse brains.407 Iron/
heme homeostasis is also critical to antioxidant activity via
enzymes such as catalases and peroxidases, and functional heme
deﬁciency, symptomatic by heme binding to amyloids and the
up-regulation of heme synthesis in AD,386 could arise from the
observed heme interaction with Aβ, causing direct oxidative
stress.254,257,255,259
Whether iron dyshomeostasis occurs before other dyshomeo-
stasis as suggested by some authors386,408 remains to be
established, but the homeostasis of various metal ions are in fact
intimately related. An important example of this is
ceruloplasmin,409 suggested to play an important role in
AD.410,411 It is a six-domain multicopper oxidase with the
structure shown in Figure 8 (2J5W.pdb),412 with three
mononuclear T1 copper sites (dark-blue) and a trinuclear
combined T2/T3 copper site (cyan). An additional, solvent-
exposed transition metal site, possibly where a substrate Fe2+
binds, is shown in orange, and a Ca2+ site is shown in gray.
Ceruloplasmin carries most of the copper in the serum413
and oxidizes several substrates by electron abstraction and
transfer to O2 bound by copper at the T2/T3 site, which is
four-electron reduced to produce water as in other multicopper
oxidases.414−416 Among its substrates is Fe2+, that is,
ceruloplasmin functions as a ferroxidase,417,418 oxidizing Fe2+
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to Fe3+. Ceruloplasmin has an antioxidant function in
vivo419−421 and has been linked to neurological disease.422,423
Mutations in ceruloplasmin can lead to loss of catalytic function
resulting in a disease known as aceruloplasminemia, where iron
accumulates in neurons, causing diabetes and neurodegenera-
tion,424 oxidative stress, motor deﬁcits, and dementia.425,426
Ceruloplasmin is expressed in neurons423 and is membrane-
anchored in astrocytes427 that are central to the brain’s
homeostasis, including metal and oxidative stress control,
express the extracellular metalloproteases that degrade
amyloids,94 and may be dysfunctional during neuronal
degeneration.428,429 It is plausible that membrane ceruloplas-
min is required for immediate oxidation of Fe2+ to Fe3+ as
required by transferrin,427 before Fe2+ otherwise engages in
toxic Fenton chemistry (vide inf ra). Thus, lack of catalytic
function of ceruloplasmin, for example, due to absence of
copper transfer from dysfunctional astrocyte MT-3 or
modiﬁcation of ceruloplasmin itself, as recently seen with
carbonylation from oxidative stress correlating with Parkinson’s
disease,430 could lead to accumulation of toxic Fe2+ and
associated oxidative stress and iron dyshomeostasis. To support
this hypothesis, increased apo-ceruloplasmin levels and
decreased ceruloplasmin activity has been observed in AD
patients.431 Ceruloplasmin deﬁciency, probably via iron
deﬁciency in tryptophan hydroxylase, also produces serotonin
deﬁciency.432 This could also explain the decreased transferrin
levels observed in AD.388 If so, the ferroxidase activity of
ceruloplasmin comes into close pathogenic relationship with
APP, which was recently shown to regulate iron homeostasis by
ferroxidase activity in a similar way, and this function was
inhibited by Zn2+.290 In these cases, Cu/Zn dyshomeostasis
would then be a causal factor in both iron dyshomeostasis,
oxidative stress, and the amyloid cascade.
4.9. The Quest for Metal-Chelating AD drugs
Because of the discussed recent breakthroughs in AD research,
bioinorganic chemistry is entering the AD ﬁeld in full force, and
metal chelators are being rapidly developed for possible
treatment of AD.18,73,433−450 Some of the therapeutic aspects
associated with chelation therapy in AD have recently been
reviewed.451,452
Particularly notable in this development was clioquinol453
(iodochlorhydroxyquin; see Figure 9), an anti-infectious drug
that is also a Zn- and Cu-chelator77 that reduces Aβ load in AD
patients, and its derivatives.454,455 Clioquinol has been
suspected of causing subacute myeolo-optic neuropathy
(SMON) in Japan after massive use during the 1960s, although
the direct causality has been debated.456 Because SMON aﬀects
the spinal cord, eyes, and peripheral nerves and leads to
blindness and paralysis, it is plausible that overdoses of
clioquinol, if responsible, impair metal homeostasis in the
CNS, leading to the observed symptoms. Thus, the SMON
cases are important reminders of the danger associated with
application of chelators to rebalance metal homeostasis,
because this treatment is constrained by a narrow therapeutic
window determined by the Kd range that speciﬁcally binds the
target without stripping metal ions from vital enzymes.
Sometimes, chelators such as clioquinol are referred to as
metal−protein-attenuating compounds (MPAC) assuming that
they cause metal release from peptides and resumption of Aβ
clearance.457 If so, competitive binding requires the chelator to
have higher metal ion aﬃnity than Aβ; for Cu(II) and Zn(II),
Kd is typically ∼10−10−10−9 M and ∼10−7 M, respectively,
depending on concentrations and pH.192 As discussed
recently,192 an eﬀective MPAC should then have a Kd of
perhaps ∼10−10 M to release Cu(II) from Aβ, or 10−8 M to
strip Zn(II), but should not strip Cu(II) or Zn(II) from
systemic sites (<10−10 M, e.g., 10−12 M for serum albumin458).
The Kd's of 1:2 metal−clioquinol complexes at neutral pH are
∼10−10 M for Cu(II) and ∼10−9 M for Zn(II).459 The 1:1 and
1:2 complexes of Cu(II) and Zn(II) with clioquinol display
distorted tetragonal and trigonal bipyramidal coordination
geometries, respectively.460 Although these were achieved at
very high clioquinol concentrations, they suggest that clioquinol
can work directly as an MPAC.
Copper-binding proteins with multiple binding sites involved
in other neurological diseases display Kd's from the 10
−18 M
range (γ-synuclein461) to the 10−10−10−9 range (Parkinson’s
disease-related α-synuclein462). The octarepeat copper binding
site in prion protein, which involves histidine coordination, may
also have a Kd of ∼10−10 M, similar to the histidine
coordination mode for Cu(II)−Aβ, possibly somewhat
larger,156 with several other amide-involving, concentration-
dependent low-aﬃnity sites established as in Cu(II)−Aβ.210,463
Figure 8. The structure of the multicopper oxidase ceruloplasmin at
2.8 Å resolution (2J5W.pdb),412 with its six active site coppers shown
in dark blue (mononuclear T1 sites) and cyan (trinuclear O2-reducing
T2/T3 site). The additional, solvent-exposed transition metal site is
shown in orange, and the Ca2+ site is shown in gray (Picture made
with Pymol).
Figure 9. Clioquinol, left, and an example of its coordination to metal
ions, right.
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However, given the weaker binding of Zn(II), it has also been
noted that apparent Kd's up to 10
−6 M may strip Zn(II) from
amyloids.228
In APP, there are both Zn(II) and Cu(II) sites of possible
regulatory function with Kd's of ∼10−6 M288 and 10−8 M,339
again 2 orders of magnitude larger for Cu(II), and close to the
solvent-exposed (free) limit and typical for nonactive site,
loosely bound, regulatory metal binding sites. Mostly over-
looked, these could in fact also be targets for chelators, and
some beneﬁts observed with chelators could be due to
regulation of APP, not MPAC function, in particular given
the weaker binding to APP than to Aβ. Thus, the possibility of
selective targeting of either amyloids (Kd ≈ 10−10 M for
Cu(II)) or regulatory APP metal sites (Kd ≈ 10−8 M for
Cu(II)) exists, with values for zinc ∼100 times smaller. Most
chelators could also work by lowering the free pools of Zn2+
and Cu2+ with Kd > 10
−7 M, as MT may do after being secreted
by astrocytes and transported through neuronal membrane
receptors such as megalin.464 Therefore, while often discussed
in terms of MPAC function, there are in fact at least three
modes of function of chelators in AD, depending on their Kd
and cellular localization.
Other prominent examples of chelators include the lipophilic
metal chelator DP-109, which reduces amyloid pathology in
APP-transgenic mice.465 Various other Cu−Zn chelators are
known to eﬀectively inhibit amyloid formation in AD
transgenic mice.454 The chelator PBT2 has displayed particular
potency and is currently in phase II studies and used as a lead in
the exploration for new commercial AD drugs.466 It is
important to stress that the molecular causation of these
compounds is not clearly established, as they may either
resolvate Cu(II)/Zn(II)−Aβ complexes by direct interaction or
by noninteracting, competitive binding, or lower free Zn2+/
Cu2+, thus reducing the free metal ion pools, which also aﬀect
the amyloid production−clearance balance, as described above.
5. OXIDATIVE STRESS AND ALZHEIMER’S DISEASE
5.1. Reactive Oxygen and Nitrogen Species
A third hypothesis of AD pathogenesis relates to impaired
oxidative stress response in the CNS leading to neuro-
degeneration.70−72,467 Oxidative stress is a natural consequence
of oxidative phosphorylation within Earth’s 21% oxygen
atmosphere, and most organisms have evolved to deal with
the potential hazards of the ROS that follow in the wake of O2
metabolism.468 The most important forms of ROS are outlined
in Figure 10, emphasizing their electronic structure and with
their spin multiplicity (number of unpaired electrons +1) given
as a superscript before the molecular formula.
Notable ROS are superoxide (O2
•−), which is the one-
electron-reduced radical anion form of normal triplet dioxygen,
dihydrogen peroxide (H2O2), and hydroxyl radical
(•OH).469,470 These are formed under all oxidative conditions,
but mainly in the mitochondria as a side product of oxidative
metabolism. It is estimated that approximately 1−3% of all
normal O2 is converted into ROS in mammals due to
ineﬃciencies of the electron transport chain,471 and this ROS
production can be enhanced if mitochondria are not working
optimally due to hypoxic or hyperoxic or other stress-related
conditions. ROS that escape the organisms’ antioxidant
defenses then oxidatively modify nearby proteins and lipids,
sometimes rendering them less stable or functional, or nucleic
acids of the DNA, leading to mutations.468
Another notable class of reactive oxidants are the reactive
nitrogen species (RNS),470,472 with the most relevant forms
outlined in the last row of Figure 10. These are primarily
derived from nitric oxide radical (•NO), which is produced by
nitric oxide synthase and serves signaling and immune defense
roles in the healthy organism,473 when •NO reacts with O2
•− to
produce peroxynitrite:
+ →• •− −NO O (superoxide) ONOO2 (1)
Shifting this reaction to the right, for example, by reduced
proﬁciency of SOD leading to elevated O2
•−, causes ONOO−
to be overproduced. ONOO− usually reacts with the plentiful
HCO3
− to generate carbonate radicals470 but will also react
readily with heme proteins and sulfur and selenium groups of
relevance to metal homeostasis and oxidative stress control.472
ONOO− oxidizes cysteines to cystine bridges or oxygenated
side chains,472 and “nitrosative stress” manifests itself, for
example, as nitrosylations of protein side chains to impair
protein function and stability and deamination of DNA474
aﬀecting both transcription and mitochondrial metabolism.475
Even before considering the vast evidence for metal ion
dyshomeostasis and oxidative stress in AD, metal ions play key
roles in both ROS production and clearance. Metal ions readily
bind ROS and RNS as ligands, and both copper and iron
produce hydroxyl radical in solvent-exposed cellular environ-
ments, notably via variations of the simplest form of the Fenton
reaction:476,477
+ → + +
+ → + +
+ + • +
+ + − •
Fe H O Fe HOO H
Fe H O Fe OH OH
3
2 2
2
2
2 2
3
(2)
The actual mechanisms can diﬀer substantially478 but
commonly aggravate oxidative stress by converting H2O2 to
much more potent hydroxyl. The Fenton chemistry unites
metal ion dyshomeostasis, which shifts balance from bound to
free metal ions, with oxidative stress pathogenesis, which is
predominantly aggravated by free Cu and Fe.469 The copper
redox pair may be involved in similar types of reactions, in
particular in the presence of reducing agents such as
ascorbate:479
+ → + ++ + • −Cu H O Cu OH OH2 2 2 (3)
Figure 10. Chemical and electronic structures of normal atmospheric
3O2 and reactive oxygen species (ROS, ﬁrst two rows) and reactive
nitrogen species (RNS, last row).
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Thus, in the absence of direct toxicity of soluble Cu(II)−Aβ
oligomers,190,342 disturbed metal homeostasis resulting in
increased concentrations of free intracellular metal ions will
itself generate ROS that could lead to oxidative stress. Thus, the
two hypotheses are intimately related via a vast number of Cu-,
Zn-, and Fe-containing proteins involved in oxidative stress
modulation.480
5.2. The Role of Oxidative Stress in AD
Because of the very large energy need of the brain required to
manage the energy-requiring processes of synaptic transmission
and ion transport,481,482 mitochondrial function is particularly
sensitive in the brain, and the mitochondrial membranes are
central to the regulation of cell death and survival.70,483 It is also
well-established that mitochondrial function declines with age
and is correlated with oxidative stress and accumulated gene
defects that are particularly abundant in brain, heart, and
muscles.70
Given that AD is a neurological degenerative disorder that
has age as the main risk factor and is characterized by oxidative
stress and somewhat relieved by antioxidants,484,485 it is not
surprising that mitochondrial dysfunction and impaired
metabolism are early symptoms in AD.13,71,72,486,487 AD is
accompanied by direct structural damage to the mitochon-
dria488 and reduced glucose utilization.489,490 Thus, although it
is not clear whether mitochondrial dysfunction precedes or
follows other pathogenic events, it is central to AD.
Oxidative stress has been suggested to be a primary cause of
AD,491,492 perhaps together with other deﬁning triggers, as
claimed in the “two-hit-hypothesis”.493 Local severe hypoxia,
for example, arising from ischemia, leads to oxidative stress
because of suboptimal mitochondrial metabolism or damage
and plays a signiﬁcant role in AD.494,495 Hypoxia leads the
mitochondria to produce more ROS, thereby triggering
oxidative stress response mediated by the transcription factor
HIF,496 which is not degraded by the iron enzyme prolyl-
hydroxylase when either iron or O2 levels are low.
497 Thus, HIF
provides another link between iron dyshomeostasis (section
4.6) and oxidative stress.
Oxidative stress can however also be caused by the amyloid
cascade. As discussed above, Aβ accumulates and impairs
mitochondria,122,123,125 possibly via apoptosis induced by Aβ
complexes binding to proteins such as alcohol dehydrogen-
ase.498 Whether Aβ passes the mitochondrial membrane or is
spliced oﬀ APP inside the mitochondria is currently
unknown.70 Any toxic eﬀects on mitochondria may itself
produce ROS, and the amyloids, at least in the toxic Cu(II)
oligomer form, are themselves ROS generators. So even if
oxidative stress somehow precedes Aβ toxicity, both eﬀects are
mutually enhancing, creating a detrimental positive feedback499
that is normally checked by Aβ clearing.
5.3. Links between Oxidative Stress and Other Pathogenic
Events
Hypoxia up-regulates β-secretase thereby disturbing the
amyloid production-clearance balance and facilitating AD
pathogenesis.88,90 Oxidative stress has also been found to
contribute to amyloid production by changing the balance in
expression of the three secretase types.500 The mechanism of
this regulation could involve MT and HIF, because both MT-
1501 and MT-3502 are induced by HIF and the normal, MT-
promoting metal-responsive transcription factor-1 (MTF-1).503
Hypoxia also reduces the uptake and transport of glutamate in
astrocytes, which could further facilitate excitotoxicity.504
Much more direct evidence for oxidative stress being an
underlying cause of the amyloid cascade comes from recent
ﬁndings of a positive feedback loop between γ- and β-secretase
activity triggered by oxidative stress.88 β-secretase expression is
increased by oxidative stress,505,506 which could explain why
hypoxia up-regulates β-secretase, since hypoxia leads to local
oxidative stress from metabolic ineﬃciency, and mitochondrial
inhibition has been shown to also up-regulate β-secretase in
rats.507 But γ-secretase activity also increases with oxidative
stress and is a cause of the increased β-secretase activity,88
recently found to be mediated by the produced Aβ42.508
Because oxidative stress naturally correlates with age,
accumulated gene errors, and exposure to exogenous risk
factors, it explains many risk factors not explained by the
amyloid cascade. Also, a positive feedback loop might initiate a
sudden, vicious pathogenic cycle upon reaching certain ROS
thresholds,491 potentially explaining the rapid disease pro-
gression of AD. Still because metal ions play key roles in the
antioxidant system, these ﬁndings require a uniﬁcation.
A central defense against oxidative stress is the SOD-1 and
SOD-3 isoforms, which depend on Cu(I)/Cu(II) and Zn(II) in
their active sites. While SOD-3 is extracellularly expressed,
SOD-1 is located in the intermembrane space of the
mitochondria and degrades superoxide that escapes from the
mitochondria.310 Mutations in this enzyme are known to cause
ALS509,510 directly demonstrating the importance of oxidative
stress in neurodegenerative disorders. Cu,Zn-SOD catalyzes the
two half-reactions
+ → +
+ + → +
+ − +
+ + − +
Cu O Cu O
Cu 2H O Cu H O
2
2 2
2
2
2 2 (4)
Modiﬁcation of the SOD-1 active site, either by ∼130
mutations identiﬁed so far (a cause of familial ALS511) or by
post-translational modiﬁcations, may lead to disrupted metal
sites and partial unfolding and a gain in toxic function that is
considered a main cause of familial ALS.273,512,513 The
coordination geometry of the active site of extracellular SOD-
3514 is shown in Figure 11. Cu(II)/Cu(I) and Zn(II) are
separated by a deprotonated histidine, which may be important
in modulating the catalytic cycle of eq 4. Any decrease in metal
content, for example, from reduced binding aﬃnity of Zn(II) or
Cu(I)/Cu(II), from reduced overall stability of the protein,
from stress-induced modiﬁcations of the protein that reduce
metal aﬃnity, or simply from reduced Zn(II)/Cu(I)/Cu(II)
transfer due to functional metal ion deﬁciency, could impair the
function of this enzyme with devastating consequences for the
oxidative-stress defenses. Notably, unfolding is correlated with
metal loss, so stability/unfolding and metal content mecha-
nisms may occur in concert.515,516 These ideas are currently
pursued in relation to ALS but are relevant also to the neurons
involved in AD.517−519
Another element that deserves mentioning in the oxidative
stress response is selenium, which is abundant in ﬁsh and is an
ingredient of glutathione peroxidase, an important antioxidant
enzyme that converts H2O2 to water via GSH, eq 5:
+ → +2GSH H O GS SG 2H O2 2 2 (5)
Selenium may also detoxify heavy metals such as Hg by
direct binding and excretion from human tissue,520 but as
recently reviewed, there are no clear indications of a beneﬁcial
role of selenium in AD.521
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H2O2 can also be reduced by various peroxidases in addition
to MT, SOD, and GSH, and several of these depend directly on
the available heme iron pool, because both some peroxidases
and some catalases are heme enzymes.522,523 Disruption of the
balance between the free and bound iron pools may thus
contribute to oxidative stress imbalance both by increased
production of ROS and by reduced degradation of ROS. ROS
in themselves, in particular superoxide O2
•−, also aﬀect
neuronal signaling by activation of NMDA-R, and enhanced
expression of SOD reduces glutamate sensitivity, directly
linking metal-dependent ROS scavenging to glutamate signal-
ing.70,524
In conclusion, oxidative stress pathogenesis correlates with
metal ion dyshomeostasis where the bound metal-ion pool
protects against ROS/RNS via antioxidant enzymes, whereas
the free metal-ion pool produces them via Fenton chemistry.
Thus, these two hypotheses can be united with causal relations
among various pathogenic events, and metal ion dyshomeo-
stasis, the shift from bound to free metal ion pools, can explain
many features of oxidative stress associated with neuro-
degeneration.377
6. METALLOTHIONEINS AND ALZHEIMER’S DISEASE
6.1. Structure, Expression, and Roles of Metallothioneins
If a protein is implicated in dyshomeostasis, it can be due to
changed production or clearance or protein modiﬁcation, either
post-translationally or due to mutations. To understand
causative factors of zinc dyshomeostasis in neurological
disorders, three classes of proteins are particularly relevant:10
metallothioneins (MT),525 ZIP transporters,281 and Zn trans-
porters (ZnT),164,526 the latter transporting Zn2+ across
membranes to the cytoplasm. In ZnT3-knockout mice, free
Zn2+ accumulates from intracellular stores not associated with
the synaptic vesicles, pointing toward MTs as central to the
buﬀering of bound and free zinc pools.297
MTs527,528 are small (60−68 residues) cysteine-rich proteins
that bind Cd(II), Cu(I), and Zn(II).529−531 The known
isoforms of mammalian MTs have seven divalent metal ions
each bound to four cysteine sulfur ligands, whereas monovalent
metal ions such as Cu(I) may bind in higher numbers than 7,
with lower coordination numbers of 2 or 3.530,531 Cd(II) and
Zn(II) are symmetric d10 ions giving formally Td coordination
geometry, but the protein renders all metal sites inequivalent,
imposing diﬀerent metal aﬃnities to each metal site.532
In mammals, four main MT classes are distinguished, with
MT-1 and MT-2 present in most tissue, whereas MT-3 and
MT-4 appear mainly (but not exclusively) in specialized tissue
such as the brain and skin.533 Brain MT-1/MT-2 is mainly
expressed in glia cells and mainly in the astrocytes534 that
maintain homeostasis in the CNS, the integrity of the BBB, and
the metabolism of neurons,464 express extracellular metal-
loproteases that degrade amyloids,94 and accumulate toxic
exogenous metals such as Pb (possibly in MTs).316 MT-3 is
particularly abundant in ZEN and astrocytes535 in the cerebellar
cortex, and in particular in the hippocampus degenerated early
in AD,4,8 in amygdala, and in the olfactory bulb.10,536 In human
MT-1 and MT-2 (see structure537 in Figure 12), Zn(II) is the
dominating metal bound, whereas both Cu(I) and Zn(II) are
found in MT-3.538 There are more than 10 isoforms of MT-1,
two of MT-2 (MT-2a and MT-2b), and one of MT-3/MT-4.539
MT-1 and MT-2 are highly sequence-similar, whereas MT-3
is the only MT isoform with a negative total charge, due to its
acidic insert. MT-3 is thus substantially negatively charged,
while other MT isoforms are nearly neutral. In mammalian
cells, most MTs appear to be N-acetylated at the N-terminus,
reducing the charge further.540
6.2. Speciﬁc Functions of Metallothioneins
MTs are responsible for transport, storage, and regulation of
zinc and copper,541,542 detoxiﬁcation of heavy metals543,544
(most Cd(II) is bound to MT in vivo),545 antistress
functions,546 including in particular oxidative stress,539,547
anti-inﬂammation548 and cell regeneration,549,550 and anti-
apoptosis.539 MT transcription is substantially (>5-fold) up-
regulated by free Zn2+, stress-induced interleukins,539,551
Figure 11. Extracellular Cu,Zn-superoxide dismutase (SOD-3)
(2JLP.pdb at 1.7 Å resolution). Cu (orange) is to the left, whereas
Zn (blue) is to the right. Between them is a bridging histidine
imidazolate. See ref 514 for details.
Figure 12. Structure of the α-domain of human MT-2 with four
Cd(II) ions bound (structure 1MHU.pdb, ref 537.).
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glucocorticoid,541,552,553 epinephrine and norepinephrine,554
heavy metals such as Cd(II), or ROS.527,555 MT induction
occurs by Zn2+ binding to the zinc-ﬁnger transcription factor
MTF-1.556,557 All MT genes contain several metal-responsive
elements (MRE) in their promoter regions.555
The loss of Zn(II) from MT most likely occurs upon heavy
metal substitution or thiolate oxygenation and subsequent
cystine bridge formation by ROS.539 In the harbor porpoise,
large fractions of the total Cd, Cu, and Zn, but not Hg, were
bound to MTs,558 indicating that Cd toxicity, but not Hg
toxicity, is countered by MTs. The role of MT in controlling
zinc homeostasis is seen in the fact that it prevents both zinc
deﬁciency and toxicity.559
Thionein (T), the apoprotein form of MT, removes Zn2+
from a wide range of inhibitory sites, thus activating a number
of enzymes selectively without impairing enzymes that use
Zn(II) in active sites560,561 or zinc-ﬁngers.562,563 On the other
hand, Zn-MT is known to transfer Zn(II) to a variety of
enzymes,564 for example, carbonic anhydrase,565 and to zinc-
ﬁngers of, for example, estrogen receptors,566 indicating that
MT is a central regulator of Zn availability in zinc-dependent
proteins.567,568 This transfer can be redox-dependent, for
example, via coupling to the glutathione GSH/GSSG redox
couple.561
The redox potential of MT of approximately −366 mV
means that upon oxidation of cysteines, MT can release zinc to
transcription factors involved in oxidative stress defense, and
thus function as a central redox sensor of the brain.10 This
process can be enhanced by glutathione disulﬁde
(GSSG).569,570 MT substantially reduces oxidative stress in
rats and mice.571−574
6.3. Investigated Roles of Metallothioneins in AD
Due to the protective role of MT against apoptosis,575,576 its
role in zinc- and copper-homeostasis327 and the central nervous
system,464,577,578 and the abnormal MT expression in AD
brains,579,580 MT is now appreciated as playing a signiﬁcant, yet
poorly understood role in AD.581−583 MT also plays major roles
in other zinc-related disorders such as diabetes,584 ALS,273
autism,271 epilepsy,585 and multiple sclerosis586 and in a variety
of aging processes,587 where MT is among very few proteins
that correlate positively with life longevity in mice.588 Absence
of MT reduces cognitive function in mice589 and renders them
less resistant to induced seizures.590
MT-3 levels are generally reported to be changed in patients
with AD, but the changes are similar to those for zinc with
regional redistributions and diverging reports,579,580,591 whereas
MT-1 and MT-2 are generally up-regulated.592,593 MT-1 and
MT-2 up-regulation in AD and other neurological disorders
may be a host defense response reﬂecting the pathology and
inﬂammatory signals, which induce MT via glucocorticoids or
elevated free intracellular Zn2+ binding to MTF-1.527 However,
Zn-MT-1/MT-2 levels in the liver are reduced despite this up-
regulation,594 suggesting a pool of (possibly modiﬁed)
apothionein or MT bound to other metals than Zn(II).
MT-3 can limit cell death and enhance neurite (axon/
dendrite) growth by identiﬁed signaling pathways595,596 and
protects neurons from cerebral ischemia in mice.597 The
protein is, like MT-1/MT-2, released from housekeeping
astrocytes428,429 during brain injury and blocks axon regener-
ation while it eliminates ROS.598 Matrix metalloproteases that
degrade extracellular amyloids and require Zn(II) are also
expressed by astrocytes.94 Once the oxidative stress is
eliminated, MT-3 is down-regulated so that neuronal
regeneration can proceed.583 Thus, MT-3 has a periodic
response to neuronal insult that involves both cell clearance and
regeneration, whereas other isoforms are uniformly protec-
tive.464,591 MT-3 can bind more metal ions and exhibits more
dynamic mixtures of metalloforms, that is, its role in Zn-
buﬀering and sensor/signaling in ZEN is plausibly diﬀerent
from other MT isoforms.599
Reactive astrocytes with high expressions of MT are found in
AD patients (astrogliosis), and the correlation is signiﬁcant
enough to suggest MT levels as a marker of AD.600 MT-1/MT-
2 is released to extracellular space by astrocytes601 to promote
neuronal regeneration via signal transducer and activator of
transcription 3 (STAT3),602 a central transcription factor that
activates a number of genes involved in cell growth,
diﬀerentiation, and apoptosis. Together with MT-1/MT-2,
other protective extracellular proteins such as SOD-3 and prion
protein are also released from astrocytes during neuron
damage.464 Extracellular MT-1/MT-2 is internalized by near-
by neurons via megalin receptors on the neuronal cell
surface.464
Given their buﬀering roles and protecting role in scavenging
Cu(II)−Aβ,247 MTs may constitute a “gold standard” for the
rational design of new MPACs. Both MT-3603 and MT-2604
protect neurons from the toxicity of Aβ peptides, and MT-3 can
reduce neurodegeneration in mouse hippocampus.605 Most
importantly, it was recently shown that Zn−MT-3 extracts
Cu(II) from the Cu−Aβ40 complexes in exchange for
Zn(II),247 and MT-3 interaction renders the amyloids nontoxic,
indicating that the toxic amyloid oligomers or precursors to the
toxic oligomers contain Cu(II) or Zn(II).606 Recently, a similar
ability to prevent Aβ oligomer formation was conﬁrmed for
MT-2,607 although studies of MT-2 and MT-3 binding to the
protein transthyretin and Aβ suggest that MT-2 may not aﬀect
amyloids in the same way as MT-3.608 MT-2 injected into mice
subject to AD-like pathology (Tg2576-type) improves
cognition but also increases plaque load.582
As discussed in section 4.2, the Kd's for Cu(II) and Zn(II)
binding to Aβ lie typically around 10−10−10−9 M and ∼10−7 M,
respectively.192,609 The regulatory Cu2+ and Zn2+ sites of APP
display Kd's of ∼10−8 M339 and ∼10−6 M,288 that is, 1 order of
magnitude weaker binding, and the Zn2+ site regulates α-
secretase activity.288 As mentioned, Cu(II) typically binds more
strongly than Zn(II) to most chelators due to the Irving−
Williams series.250 For comparison, active-site Zn(II) in zinc
enzymes such as carbonic anhydrase610 and Cu,Zn-SOD611 is
more strongly bound, with typical Kd's of ∼10−11 M.
568 An
eﬀective chelator against metal−amyloid toxicity should not
outcompete these sites, suggesting an MPAC in a very narrow
range between bound and free pools with a Kd of ∼10−10 M for
Cu(II) and perhaps 10−8 M for Zn(II). Apo-MT-1/2 displays
Kd's for Zn(II) on the order of 10
−13 M567,612 but is still the
main Zn(II) buﬀer within eukaryotic cells,613 because Zn(II)
transfer occurs stepwise from partially metalated forms, notably
Zn5−MT and Zn6−MT with Kd's of ∼10−10 M,
614 very close to
the optimal range suggested above. Zn7−MT-1/2 has been
found to have one weakly bound Zn(II) with Kd ≈ 10−8 M and
donates this Zn(II) to other chelators.614 For MT-3, an
additional eighth Zn(II) binding site has been identiﬁed that is
not present in MT-2.615
For both MT-2 and MT-3, stronger binding of Cu(II) as
expected from the Irving−Williams series has been conﬁrmed
by density functional calculations.616 It would be desirable to
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design MPACs selectively targeting each metal ion, to prevent
dangerous stripping of active site metal ions,192 and MT could
be a central model for such designs. The natural chelator
function of MTs also applies to MT-3, which scavenges
oxidative-stress-generated Cu(II).617
The degradation of MTs by cysteine proteases such as
cathepsin B occurs actively in lysosomes,618,619 and by certain
other proteases in the cytosol.539,620 This is interesting because
cathepsin B has also been shown to have a neuroprotective
eﬀect, plausibly by degradation of Aβ.621 Thionein is more
prone to degradation, suggesting that clearance is enhanced if
metal sites are modiﬁed to reduce the binding aﬃnity. This
could explain why the Cu/MT ratio may be a reliable marker of
AD progression;622 that is, the free Cu2+ pool increases more
than the MT levels and is correlated in time with AD
progression.
7. METABOLISM, AGING, DIABETES, AND
ALZHEIMER’S DISEASE
7.1. Metabolism, Aging, and AD
The risk factors of hypercholesterolemia, obesity, and diabetes,
and the beneﬁts of exercise and mental activity associated with
AD may reﬂect that imbalances in mitochondrial metabolism
are early pathogenic events.13,623 As advocated by the free-
radical theory of aging,468,624,625 slower metabolic rate, for
example, induced by moderate hypoxia,626 enhances life span
by producing less radical oxidative damage from mitochondrial
activity, whereas hyperoxic conditions shorten life span of
cultured cells.627 Evidence for the association between
mitochondrial ROS and aging was obtained from longevity
observed in mice overexpressing mitochondrial catalase.628 It is
important to distinguish local severe hypoxia, for example, from
ischemia, and moderate hypoxia, for example, that associated
with living at high altitude. The latter will contribute to the
eﬀect of controlled, slower metabolism, whereas the former
generates mitochondrial damage and ROS.496
During aging, a number of signiﬁcant changes occur that are
related to changing gene regulation and protein expression.629
Some of these normal aging processes converge with symptoms
of AD: (1) genes that enable synaptic function, for example,
NMDA-R, GABA-R, and voltage-gated Na channels, are down-
regulated;629 (2) Ca2+ levels are elevated in older people630 and
calcium homeostasis is down-regulated364,629 in proportion to
down-regulated synaptic transmission; (3) inﬂammation and
stress responses, for example, MT-1/MT-2, integrin, and heat
shock proteins, are up-regulated;629 (4) mitochondrial function
is impaired and down-regulated.629 Hormonal changes are
diverse: leptin and insulin receptors are up-regulated, whereas
melatonin, controlling the circadian rhythm (vide inf ra), and
somatostatin, involved in neurotransmission, are down-
regulated, consistent with less synaptic activity.629
Consequently, in many ways, the AD brain is a brain that has
aged faster than the average brain,364 and one could in some
aspects view AD as an “accelerated-aging” disorder.631 This is
supported by the broad clinical spectrum of the disease, as well
as the occurrence of amyloid plaques in people without AD.631
AD patients also display reduced glucose uptake, which is one
of the common biomarkers of AD.6 AD is currently often
diagnosed via memory impairment conﬁrmed by presence of
senile plaques during post-mortem autopsy, with biomarkers
playing a rather small role.6 Diﬀerences between AD brains and
accelerated aging brains should be obtainable from comparing
AD brains to older brains instead of same-age controls and
would be relevant to deﬁne how AD distinguishes itself from
the accelerated aging brain, and not just the same-age control
brain. For example, the expression of metalloproteins such as
MT-3 are elevated in elder but are abnormally distributed in
AD,535 which is clearly not simply an accelerated aging eﬀect
but possibly a result of redistributed zinc levels and astrocyte
dysfunction (vide inf ra).
In the aging body, the mitochondrial down-regulation
correlates with less physical and mental activity (synaptic
function is also down-regulated) and is associated with
oxidative DNA damage consistent with the free radical theory
of aging.629 One of the most sensitive mitochondrial proteins
subject to oxidative damage is mitochondrial aconitase, an
iron−sulfur containing enzyme in the Krebs cycle that converts
citrate to isocitrate, which is impaired by superoxide.632 Thus,
one of the ﬁrst critical imbalances in oxidative stress-induced
aging may be associated with aconitase.632 This is interesting
since MT transfers Zn(II) to mitochondrial aconitase in mouse
hearts and may thus regulate the Krebs’ cycle,633 as also
indicated by the eﬀect of zinc on the isocitrate/citrate
equilibrium of aconitase.634 Free Zn2+, which would arise
from dysfunctional MT, has instead been found to inhibit
cytochrome c oxidase334,635−637 and mitochondrial aconitase
synthesis,638 thus reducing metabolism and energy production.
Another important marker of aging is the shortening of
telomeres, the DNA sequences that protect the ends of
chromosomes from damage.639 The reverse transcriptase
telomerase adds new protecting DNA sequences to telomeres
of eukaryotic stem cells and some cancer cells, but not to other
cells, which are then subject to a “count-down” of telomere
shortening upon replication that may eventually result in
chromosome fusion.640 The activity of telomerase, as a reverse
transcriptase, is up-regulated by Zn2+, thus preserving the ability
to replicate641 and in some sense “slowing the count-down”,
whereas artiﬁcial Zn-ﬁnger motifs can repress telomerase.642 A
casual link between zinc homeostasis and telomere shortening,
including an inverse relationship between MT expression and
telomere shortening in people older than 80 years has recently
been indicated.643 Thus, zinc homeostasis may be centrally
positioned within the biological clockwork of aging, with the
free Zn2+ pool at least to some extent directing the speed of the
clock.
7.2. Zinc: A Link between Diabetes and AD?
While being completely diﬀerent diseases in terms of pathology
and progression, there are several underlying similarities
between AD and type II diabetes:644 AD brains are insulin-
resistant,384,645 and such insulin resistance leads to cognitive
decline;646 both diseases are accompanied by oxidative stress
and have age as a risk factor;647 diabetes is itself a risk factor for
AD,20,21 as is obesity and hypercholesterolemia;10 and diabetes
aggravates AD symptoms.648 The similarities between protein
aggregations in the two diseases were recently reviewed.649
A common feature of the diseases is zinc dyshomeostasis,
widely documented in both type-I and type-II diabe-
tes.647,650−653 Increased urinary excretion of zinc is observed
in diabetes patients suggesting elevated free Zn2+ as in
AD.654,655 On the other hand, type-I and type-II diabetes are
usually associated with higher vs lower blood zinc levels,
respectively.650,656,657 Zinc can partly remedy type-II diabetes
by showing insulinomimetic activity,658 but while its role in
insulin signaling and integrity, storage, and transport is
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established,651,659 the mechanism of this function is not
understood.650
Zn2+ is required for the stable storage of insulin, because it
binds in the center of the insulin hexamer complex and is
tightly correlated to insulin storage and release,650,660 see Figure
13.661 Zinc dyshomeostasis changing the equilibrium between
free and bound zinc pools might disrupt this structural integrity,
possibly explaining the reduced glucose utilization in AD.
Furthermore, the insulin degrading enzyme is also an important
Zn(II)-dependent amyloid-degrading protease (Figure 7).292
These suggestions are supported by the observation that
MT-knockout mice experience increased zinc loss via the
pancreas,662 showing that dysfunctional MTs may contribute to
zinc dyshomeostasis also in diabetes. The beneﬁcial eﬀect of
MT on type-2 diabetes is well established,650,663 and MT is of
central importance in preventing diabetic cardiovascular
complications,664−666 diabetes-related oxidative stress,667 dia-
betes-related leptin imbalance, and obesity.668,669 Certain MT
polymorphisms are correlated with type-2 diabetes.670 Zn-
induced MT remedies induced diabetes by protecting against
oxidative stress,572,573 and MT function has been observed to
be impaired in type-2 diabetes.671 Reconstituted zinc transfer to
relevant targets, including insulin, SOD, or transcription factors,
are plausible explanations for these beneﬁts,672,673 although zinc
alone also has a beneﬁcial eﬀect uncorrelated with the MT that
zinc induces.573
Since ROS cause insulin resistance,674,675 antioxidative
dysfunction is a possible focal point of common pathogenic
mechanisms in AD and diabetes, and MT’s role in type-2
diabetes could also relate to its antioxidant function, which is
intimately related to its zinc binding.676 However, another link
is iron dyshomeostasis, which disrupts the eﬃciency of the
mitochondria’s energy production and could both aﬀect glucose
utilization and insulin balance and cause ROS via Fenton
chemistry.161,677 Mutations in ceruloplasmin, the multicopper
ferroxidase important in iron homeostasis described in section
4.8, ave been reported to cause both diabetes and neuro-
degeneration.424
The links between diabetes and AD are currently mainly
hypothetical and should not be overemphasized, but the
common pathological features could in principle be explained
mechanistically by zinc dyshomeostasis, and this hypothesis
warrants further investigation.
8. METHIONINE SYNTHASE, VITAMIN B12, AND
HOMOCYSTEINE IN ALZHEIMER’S DISEASE
As described above, hyperhomocysteinemia (∼15−50 μmol/
L)678 is correlated with risk of AD22,24,679 although there are
diverging reports as recently reviewed.680 Homocysteine levels
are also elevated in cerebral ischemia,681 cardiovascular disease
(together with Cu),682 and various other disorders.683−685 In
humans, homocysteine is converted to methionine by the
enzyme methionine synthase (MES),686 which plays an central
role together with S-adenosyl methionine (SAM) in methyl-
ation pathways and in nucleotide synthesis in the CNS.678,687
MES both depends on the cobalt-containing cobalamin
cofactor for transferring methyl in an SN2 reaction and requires
Zn(II)688,689 as do other methyl-transfer enzymes,690 most
likely to enhance the nucleophilicity of homocysteine by
lowering the pKA and deprotonating the sulfur-bound proton
before nucleophilic attack on cobalamin-bound methyl.691
Thus, MES dysfunction due to decreased availability of Zn(II)
or vitamin B12 (including cobalt) or zinc-mimetic inhibition, for
example, by Hg,692 will lead to hyperhomocysteinemia. The
physiological eﬀects of hyperhomocysteinemia and vitamin B12
have been reviewed recently,678,693 and some of the most
repeatedly observed eﬀects are elevated Ca2+ levels, oxidative
stress, cell death/caspase-3 activation, and higher intracellular
Aβ42.
The underlying cause of the hyperhomocysteinemia observed
in AD can be due to either production or clearance issues. In
terms of clearance, Zn(II)-deﬁcient MES could lead to
homocysteine buildup, possibly explaining why B12 or folic
acid supplements do not slow AD progression,694,695 although
this could also be because the homocysteine balance is quite
downstream from the causative events in AD. Also,
colocalization of exogenous homocysteine with amyloids696
could indicate that homocysteine is not cleared because it is
bound to Zn(II) and Cu(II) in extracellular amyloid deposits,
although this remains to be investigated further.
Importantly, the methylation pathways controlled by MES
and SAM also underlie the conversion of norepinephrine to
adrenaline by phenylethanolamine N-methyltransferase, which
has been found to be down-regulated in AD,697 plausibly
because of the homocysteine buildup upstream to this enzyme.
Thus, the production of norepinephrine (and hence adrena-
line) is impaired in AD, and the hormone has been found to
enhance phagocytosis of Aβ,698 which could aggravate AD. An
association between some variations in phenylethanolamine N-
methyltransferase and AD has been documented.699 As
mentioned previously, a part of the MT stress response is
due to induction of MT by epinephrine and norepinephrine,554
and if this induction is absent, it may enhance inﬂammation in
neurons usually reduced by MT.
9. ALS AND AD: SAME THING, BUT DIFFERENT
ALS and AD share a variety of pathological features:273,512,513
oxidative stress, neuronal inﬂammation, dysfunctional zinc
Figure 13. Structure of one half of the human insulin hexamer
stabilized by tetrahedrally coordinated Zn2+ in the center
(2OMG.pdb). See ref 661 for details.
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homeostasis, mitochondrial malfunction, formation of protein
aggregates (amyloids in AD; neuroﬁlaments in ALS), only a few
years survival time after diagnosis, late onset (i.e., age risk),
substantial increase in occurrences since the 1960s or 1970s
indicating some environmental risk factors that cannot be fully
explained by changes in diagnostic paradigms,700 and symptoms
of apoptosis signaling in the disease end stage.273,701 Both
disorders have a minority of familial cases (in ALS due to SOD-
1 mutations causing ∼20% of familial cases701), while the vast
majority of cases are sporadic. Motor neurons are, like neurons
in the brain, consumers of large amounts of energy, rendering
their mitochondria more sensitive to oxidative stress.
Several research groups have established that a fundamental
cause of the fraction of familial ALS relating to SOD-1
mutations is a gain of toxic function of SOD-1,702−704 and such
toxic function, for example, aggregation or partial unfolding, is
linked to reduced Zn(II) aﬃnity,705 suggesting lack of Zn(II) in
the protein. Some argue for706,707 or against708 correlation
between disease progression and protein stability. As described
recently,273 lack of Zn(II) in SOD-1 could reverse the reaction
so as to produce superoxide radicals from O2, giving
nitrosylated proteins and lipids,709 but other toxic functions
are possible, for example, partial unfolding and aggregation
coupled to new redox chemistry, such as, exposure of copper
leading to Fenton-type oxidations, eq 3. Also, β-secretase
overexpression can reduce SOD-1 activity,710 possibly by
protein−protein interactions mediated by Cu,69 providing a
possible molecular mechanistic link between AD and ALS
pathogenesis.
In contrast, sporadic ALS seems to be caused by gradually
enhanced stress leading either to steady progression of the
disease or to sudden pathogenic cascades due to key events
relating primarily to oxidative stress.491 Given the similarity in
sporadic and familial ALS pathogenesis,711 it seems logical to
assume that SOD-1 dysfunction is also a plausible cause of
sporadic ALS and familial ALS not directly related to SOD-1
mutations. Dysfunctional SOD-1 would then be caused by
post-translational modiﬁcations, for example, lack of Zn(II) for
other reasons than mutations decreasing Zn(II) binding aﬃnity.
Given MT’s role in buﬀering Zn(II), it is a plausible hypothesis
that dysfunctional MT is a cause of dysfunctional SOD-1 in
sporadic ALS, a hypothesis that has indeed been sup-
ported.701,712 This would put AD and ALS into close
pathogenic relationship, although the cellular locations
(motor neurons vs zinc-enriched neurons in hippocampus,10
possibly both due to astrocyte dysfunction) and thus
neurological consequences of the diseases would diﬀer.
Alzheimer-type tau pathology has also been associated with
SOD-1 deﬁciency, and SOD-1 was found to be reduced in AD
patients compared with other mitochondrial and extracellular
SODs.713
Mouse models of accelerated aging (SAMP10) display zinc
deﬁciency due to low expression of ZnT3.714 Very recently it
was found that MT-3 signiﬁcantly prolongs life span of ALS
model mice and reduces motor neuron loss.715 MT levels are
elevated in kidney and liver of ALS patients,716 and MT
expression is increased in the spinal cord of ALS patients.717 A
variety of heavy-metal exposures have been found to lead to
ALS718 or ALS-like symptoms.719 However, while zinc
deﬁciency was linked to ALS in a 22-person study, heavy
metals in toe nails did not correlate with ALS.720 Larger studies
and consideration of other heavy metal markers (e.g., MT
markers where most Cd is located in vivo545) instead of toe
nails would be warranted.
As in AD, in the ﬁnal disease stage of ALS, when motor
neuron mitochondrial damage reaches a certain critical level
and oxidative stress is no longer sustainable, apoptosis may be
triggered by release of cytochrome c and apoptosis-inducing
factor (AIF) from mitochondria, initiating the caspase
cascade,721 which is also regulated by free Zn2+.722
Of further interest is the possibility of a similar mode of
toxicity in the mutant SOD-1 of familial ALS and of Cu(II)/
Cu(I)−Aβ, notably given the similarities between the plausibly
partly unfolded and hence solvent-exposed SOD-1 Cu(II)/
Cu(I) site and the corresponding site in amyloids,723 sharing
doubly coordinated histidine and potentially forming ROS-
generating exposed Cu(I)/Cu(II) Fenton chemistry. As
discussed, in addition to its ferroxidase function, APP contains
both copper and zinc binding sites with potential redox
function that might be linked to amyloid processing (e.g., a
ferroxidase/SOD metabolic control function of mitochondria).
The hypothesis that the key toxic mode of Aβ is a solvent-
exposed Cu(II)-motif chemically and structurally similar to the
acquired toxic function of SOD-1 mutants would be interesting
to investigate.
10. EXOGENOUS METAL EXPOSURE AND
ALZHEIMER’S DISEASE
Since the early 20th century and in particular since 1950, the
industrial production and emissions of exogenous metals have
dramatically increased.724 This enhances the risk of exposure to
the CNS, both during development and in adults. The
neurotoxic eﬀects of non-natural metals, which are well-
established,725−728 depend on the scale and duration of the
exposure and how it coincides with the delicately tuned
developmental processes of the CNS.729 Notably, many
neurological disorders, including AD and ALS, have been
subject to accelerating prevalence in postwar history that could
be partly due to increased awareness and partly due to
exogenous factors such as urban pollution.
10.1. Aluminum
The ﬁrst exogenous metal to be identiﬁed as a risk factor in AD
was aluminum (Al).730 Aluminum is a light metal (atomic
number 13) with iron-mimetic biochemical behavior.44,731
While many toxic mechanisms of Al are known, none of
these have been causally linked to AD.45 In the 1990s, several
research groups found no elevated Al levels in AD tissue,732−734
and there were disagreeing in vivo and in vitro studies735,736
resembling somewhat those for Zn, Cu, and Fe, with highly
tissue-dependent and heterogeneous reports. Furthermore, Al
is often easily excreted737 and did not seem to penetrate to the
brain in toxic concentrations that could justify an “aluminum
hypothesis” of AD.738 Also, some reports of elevated Al were
shown to be erroneous.732 However, after substantial
controversy,739,740 Al is now mostly considered a risk factor
in AD, as reviewed recently by several authors,44−46,741
although its total weight among other risk factors is highly
debatable.147,742
Approximately 20 studies have related Al in diet and drinking
water to AD risk44,730,743−749 (more references can be found
elsewhere743). Still, most Al exposure occurs via inhalation in
Al-involving industries.725 Early or midlife exposure to Al has
been found to be a signiﬁcant cause of later AD development
among foundry workers.750 In dialysis patients, Al accumulates
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in the brain and gives rise to a form of neurodegeneration called
dialysis encephalopathy,751 with symptoms that resemble
AD.725,752 In AD brains, while Al levels were not found to be
toxic, as with other metal ions, there are large heterogeneities in
the local depositing of the metal, typically leading to local toxic
concentrations.153
The detailed toxicological aspects of aluminum are reviewed
elsewhere,725 but for the present context, it is most relevant to
note that since Al(III) is a hard Lewis acid that mimics Fe(III),
its primary toxicological targets are diﬀerent from the heavy
metals discussed below. Al(III) mainly interacts with the
mitochondria and impairs energy production, for example, by
interference with iron−sulfur proteins of the respiratory
system.753 Recent studies provide possible mechanisms for
Al’s involvement in amyloid formation in vitro178,252,754 and in
vivo,44,755 and in AD-like tau processing.756,757Aluminum
exposure was recently shown to produce iron-mediated ROS
in Drosophila of relevance to AD,758 and the ability of iron
chelators to remedy this ROS758 suggests that Al(III) has
substituted bound Fe(II/III), probably leading to free Fe2+/
Fe3+ and Fenton toxicity, which would enhance the ROS
burden and render the CNS more vulnerable to AD risk factors.
A scheme for aluminum’s interference with iron regulatory
proteins leading to increased risked of AD have been discussed
in several reviews.144,383
As other metal ions, Al(III) also binds directly to Aβ,240 is
colocalized in senile plaques,759 and may in fact produce
structural aggregates that are more toxic than those with other
metal ions, while also interrupting tau protein processing.760
The aggregation mechanisms of Al(III)−Aβ were also found to
be distinct from those of Cu(II) and Zn(II).240 In fact, it has
independently been suggested that trivalent metal ions such as
Al(III) are key to the formation of plaques,178 whereas Cu(II)
and Zn(II) are deposited in them adventitiously,761 although
these proposals clearly need more investigation.
In terms of treatment, chelates that remove Al from
hyperphosphorylated tau762 have been found to slow AD
progression by ∼50%,763 with beneﬁts up to 5 years,764
although other reports showed negligible beneﬁts of chelation
therapy.765 In summary, while pathogenic mechanisms related
to iron(III)-mimetic toxicity in AD are plausible, they remain
unproven,45,741 and the many studies correlating Al to AD need
to be investigated further to evaluate whether the relationship is
causal.
10.2. Cadmium
There is no causal evidence of a role of Cd in AD, but elevated
Cd levels have been observed in the liver of AD patients,594
whereas brain levels seem unaﬀected,168 and Cd levels have
been reported to be elevated in the cerebrospinal ﬂuid of AD
patients.766 Also, because Cd(II) is an important exogenous
Zn(II)-mimetic metal, it deserves mentioning in this review.
Cadmium is a highly toxic heavy metal with a physiological
half-life of 15−20 years, a key factor for its toxicity.767 The
European Union’s suggested maximum allowed concentrations
of Cd(II) are 0.66 μg per gram of creatinine in the urine.768 Cd
intake from food (seafood, rice, and vegetables) on average
leads to ∼1 μg of Cd intake per average person per day,
whereas the tolerable weekly intake is approximately 2.5 μg per
kg of body mass,767 but smoking or other environmental
exposures from pollution, etc., may lead to toxic doses.767 The
most common Cd exposure is from tobacco smoke,769 and
observed higher levels of heavy metals in smokers,770 notably 5
times higher cadmium levels in blood compared with
nonsmokers,771 could provide one possible reason for the
correlation between AD and Cd/smoking.772 Incidentally,
smokers also experience hyperhomocysteinemia, a risk factor
of AD.773
Cd(II) is toxic via a number of mechanisms, notably via
oxidative stress774 and zinc-mimetic chemistry.775,776 Cadmium
is below zinc in the periodic table and easily replaces it in many
chemical reactions.724,777 Cd(II) is larger, more polarizable, and
hence a softer Lewis acid than Zn(II); it is more thiophilic
(displays larger aﬃnity for sulfur ligands) than Zn(II) and can
thus displace Zn(II) in proteins where cysteine or methionine
are present. Most Cd(II) is bound to cysteines in MT as part of
normal detoxiﬁcation.778,779 Thus, Cd(II) is, together with
Hg(II) also iso-electronic with Zn(II), a key contender in
disruption of zinc homeostasis. As for Zn(II), bioavailable
Cd(II) is always found in the divalent oxidation state, with a
complete d-electron shell and a symmetric, usually tetrahedral
coordination chemistry.
Related to AD, Cd(II) may interrupt tau processing,780 and
Cd(II) bound to MT781,782 will disturb metal binding sites and
could possibly increase the free Zn2+ pool while impairing
Zn(II) transfer to zinc proteins,532 which could cause MT
dysfunction contributing to zinc dyshomeostasis,783 although
this is currently unexplored. Alternatively, due to its zinc-
mimetic properties, Cd(II) may bind directly to regulatory zinc
sites aﬀecting APP processing, causing amyloid imbalance by
direct zinc substitution of regulatory Zn2+ instead of aﬀecting
the size of free Zn2+ pool as above. There is evidence that
Cd(II) binds close to the α-secretase site in APP, thus favoring
amyloid production.784 This site is likely to be the regulatory
Zn2+ site in APP, which is also located in this region.288
Importantly, dyshomeostasis of iron may contribute to
increased uptake of heavy metals such as Cd(II),785 and as
mentioned previously, homeostasis of Cu, Zn, and Fe is
intimately related, notably via APP, MT, and ceruloplasmin.
Thus, risk factors can act in concert to produce toxic eﬀects that
cannot be evaluated as isolated entities. This insight is essential
for understanding metal-induced neurotoxicity.
10.3. Lead
Lead (mainly in the Pb(II) oxidation state) is also neuro-
toxic.725,786 It impairs neurotransmission787 and has been found
to impair social and cognitive skills in children788−790 and long-
term memory.791 The main target of Pb toxicity is the brain,792
in particular zinc and calcium sites in proteins,726 and cognitive
deﬁcits occur after exposure at commonly encountered low
doses, <75 μg/L blood.793
Links between such early exposure and late onset of AD has
been observed in primates,794,795 and it is plausible that
exposure during fragile CNS development could enhance risk
of AD later in life,42,796,797 although several studies have not
found a correlation between Pb exposure and development of
AD.42 In young rats, the morphological and synaptic impair-
ments by Pb(II) that could be causative have been described.798
The literature of Pb exposure relating to AD was recently
reviewed.42
Possible molecular pathogenic mechanisms of Pb relating to
AD may include binding to gluthathione and thereby induction
of oxidative stress.479 As for cadmium, lead is highly thiophilic
and thus interferes with zinc homeostasis by disrupting Zn(II)-
binding sites with soft ligands such as cysteine.799 In vitro Pb
exposure up to 50 μM was found to correlate with
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overexpression of APP and reduced activity of neprilysin, one of
the zinc proteases involved in Aβ degradation.800 In primates,
APP overexpression from Pb exposure was recently found to be
due to DNA methylation toxicity.801 In other in vivo studies, Pb
seemed to inhibit Aβ transport by the low-density lipoprotein-
receptor-related protein 1802,803 (LRP1; aka apolipoprotein E
receptor (APOER)), which is the membrane receptor that
transports apoE4-cholesterol to the neurons.804 Recently,
Pb(II) was also found to catalyze tau protein aggregation via
binding to His-330 and His-362.805
Interestingly, MT has been found also to bind to receptors
such as LRP1, probably to transfer Zn(II) and facilitate signal
transduction for neuronal growth.806 Adverse eﬀects of Pb
exposure are aggravated by the presence of the APOEe4 allele,
suggesting a correlation between Pb exposure and this
protein.807,808 Thus, although many mechanisms could explain
a causal eﬀect of early Pb exposure and later AD development,
more studies are needed to provide such causation, which is
currently not established.42
10.4. Mercury
Mercury (Hg) is a highly neurotoxic element,725,809−811 and
accumulated evidence now identiﬁes it as a risk factor for
AD.43,812,813 Major sources of Hg are ﬁsh consumption, the Hg-
containing alloy amalgam in dental ﬁllings,814 some vaccines,
and urban air pollution.813,815 For example, amalgam may leak
1−12.5 μg of Hg per day, with long time accumulation due to
substantial retention.810 It has been estimated that ∼300 000
newborns may have been exposed to Hg concentrations that
could cause neurological damage.816
It is known that during mouse pregnancy, Hg(0) vapor
penetrates the placental barrier and damages fetal organs
including the brain; MT protects against this penetration.817 Hg
is very BBB-penetrable (80%) and localizes in the spinal cord,
of relevance to ALS,818 and in the cortical brain, of relevance to
AD.959 A particularly toxic form, methyl mercury [CH3Hg]
+,
causes lethal neuronal damage.819 [CH3Hg]
+ from seafood
accumulates in astrocytes that express MT-1/MT-2,820 central
homeostatic cells in AD pathogenesis,429 to be discussed later.
The chemical mechanisms of neurotoxicity are several:
Hg(II) binds to soft Lewis base amino acids cysteine and
methionine in various proteins,821 notably tubulin, the
structural protein component of microtubules in the
cytoskeleton that are produced by tau protein, thereby
inhibiting binding of guanosine triphosphate (GTP)822,823
and ADP ribolyzation of tubulin,824 both required for normal
microtubule formation and hence cytoskeleton integrity,825
thus leading to cell degeneration.826 Such a cascade would also
cause tau hyperphosphorylation and neuroﬁbrillar tangles as a
consequence of heavy metal exposure to the CNS,813 which is
indeed observed upon Hg exposure,826−828 in concurrence with
increased Aβ secretion,829 Hg-induced Aβ aggregation,830
tubulin dysfunction, and apoptosis.831
In rats, Hg has been shown to interact biologically (although
probably not directly) with melatonin. Melatonin levels are
depleted upon Hg exposure, while melatonin production
increases.832−834 The chemical interaction could occur via
binding to enzymes involved in melatonin pathways or
substitution of zinc in proteins leading to zinc binding to
melatonin. On the other hand, Hg binds directly to
selenium,520 preventing selenium availability to glutathione
peroxidase, thus indirectly causing further oxidative stress. Hg
may inhibit Aβ transport by LRP-1 as Pb does,802,803 which
could explain the eﬀect of Hg on amyloid secretion.
Hg levels in AD brains have been estimated at 0.02−0.18 μg/
g tissue,835,836 or [Hg] ≈ 0.1−0.9 μM.813 Some studies have
not found any correlation between Hg from amalgam and
AD,837 although these concentrations of Hg are much higher
than Hg concentrations (0.1 nM) found to cause axon
degeneration and neuroﬁbrillar tangles in other studies826,813
However the lack of correlation between amalgam and Hg
concentrations in that study837 is inconsistent with the
consensus of Hg migration from amalgam from a wide range
of studies,838−845 suggesting erroneous monitoring of Hg.813 In
fact, even Hg from amalgam in mothers correlate with Hg in
fetal and infant tissue,846 consistent with observed Hg transfer
across rat placenta.817 Depending on the lipophilicity of various
toxic forms of heavy metals, monitoring hair, nails, blood, and
other tissue will necessarily give diﬀerent results.847 In addition,
contents in diﬀerent tissues reﬂect diﬀerent timings and periods
of exposure, namely, the pharmacokinetics.813 Thus, blood
concentrations, reﬂecting long-time exposure, of Hg, Cd, and Al
were signiﬁcantly elevated in AD patients, whereas Cu was
elevated in the cerebrospinal ﬂuid.766,848 In contrast, patients
with AD have been found to have less Hg in nails and hair
compared with controls.849
Many studies have found exogenous metal exposure to
enhance risk of other neurological disorders, notably in this
context Parkinson’s disease196,850 and ALS,851−855 which as
discussed shares many features with AD. Increased heavy metal
load has also been found in ALS patients.856−859 While
correlation is no longer disputed, causation is substantially
more diﬃcult to prove or disprove. However, natural metal
homeostasis (Cu, Zn, Fe) provides an emerging framework for
discussing exogenous metal exposure as one of many risk
factors that can perturb this homeostasis and lead to
neurological disorders such as AD.
11. NATURAL METAL CHELATORS AGAINST
ALZHEIMER’S DISEASE
Given the central role of bioinorganic chemistry in AD
pathogenesis, it is not surprising that many known beneﬁcial
dietary prevention strategies against AD in fact involve BBB-
penetrable antioxidant and metal-chelating substances.56 Many
such compounds are found as natural products or well-known
drugs for other purposes and can be obtained as part of a
diet.860−863 In addition to being antioxidant and metal-chelating
with the optimal Kd and selectivity between targeted metal ions,
these compounds should also be hydrophobic and capable of
crossing the BBB and must be of reasonable small molecular
weight and fulﬁll various other, typical criteria of drug-
likeness.445,864,865 Here, six such candidates will be discussed:
lipoic acid, N-acetyl-L-cysteine (NAC), epigallocatechin gallate
(EGCG), curcumin, melatonin, and galantamine.863,866
Lipoic acid is a coenzyme for pyruvate dehydrogenase in the
mitochondria and thus plays a role in neuronal energy
production. Already in the 1990s, it was reported to improve
cognition of rodents,867,868 and it has been in focus as a disease-
modifying treatment of AD869−871 and as part of dietary
supplement to reduce risk of AD.863 Lipoic acid contains a
carboxylate functional group and two vicinal sulfur atoms, that
is, both hard and soft Lewis-base donors, which should be
useful in targeting both more thiophilic (Cu, Zn, Cd) and
oxophilic (Fe, Al) metal ions. In its reduced form, dihydrolipoic
acid, as usually found in cells,872 it can chelate metal ions. It has
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been found to reduce oxidative stress mediated pathogenesis in
AD cells.467,873 Notably, together with acetyl-L-carnitine,
another natural antioxidant chelator, lipoic acid may enhance
α-secretase activity and thus partly restore amyloid balance874
and improve cognitive function of ApoE4 mutant mice.875
NAC, N-acetylated cysteine, is a simple, nontoxic compound
used against cystic ﬁbrosis and coughing, capable of breaking
disulﬁde bonds and dissolving mucus.876,877 NAC can also act
as a chelator878 via some of its potential donor lone pairs on
thiol, carboxylate, amine, and carbonyl. NAC is a membrane-
penetrable precursor to cysteine and is usually hydrolyzed to
cysteine or forms disulﬁdes with life times up to 6 h.879 NAC
has been shown to be beneﬁcial in schizophrenia, possibly by
inhibiting GABA-R,880 and in various other neurological
disorders.879 NAC has been shown in trials to be beneﬁcial
to patients with probable AD881 and has also been suggested as
a part of dietary prevention of AD.863 NAC can reduce
oxidative damage882 and displays antiamyloid eﬀects883 in
mouse models of AD.
EGCG is a main phenol constituent (catechin) of green tea
and contains several sites for bidentate coordination of metal
ions,467 both via vicinal hydroxy groups and via hydroxy groups
on separate rings (see Figure 14). EGCG is both BBB-
penetrable and an eﬀective M(II) chelator,884 and catechins are
found to bind Fe(II),885 Zn(II),886 and Cu(II) with associated
antioxidant reactivity.887 Also Fe(III)−gallocatechin complexes
with variable stoichiometries have been described,888,889 as well
as Al(III) complexes with Kd ≈ 10−8−10−5 M.
890 For 1:1
complexes of Zn(II) and Cu(II) catechins, formation constants
of 105−106 M−1 (corresponding to Kd's of 10−6−10−5 M) were
observed,891 enough to sequester the free chelatable M(II)
pools but too weak for outcompeteting amyloids (Kd ≈ 10−10−
10−7 M).
As a potential treatment against AD, EGCG has been found
to inhibit Aβ production in Swedish double mutant transgenic
mice (mice encoded with the mutant known to cause the severe
example of AD in a Swedish family), accordingly by promoting
the nonamyloigenic α-secretase pathway892 while at the same
time modulating tau pathology and cognitive decline.893 Other
researchers have conﬁrmed these results and identiﬁed possible
pathways of inhibition,894 while some suggest that APP
expression is reduced via iron chelation.467
Curcumin is found in the Indian spices turmeric and curry
and is known to be an antioxidant metal chelator895 that binds
to a large range of biological targets, as recently reviewed.896
Epidemological studies have found that the incidence of AD
among people in their 70s was about 4−5 times smaller in India
than in the US and that curry consumption correlated with this
tendency.897,898 While researching the beneﬁcial eﬀects of
curry, curcumin was found to protect against Aβ-induced
cognitive deﬁcits899,900 by direct binding to amyloid in vitro and
in vivo.901 The Kd's for Cu(II)−curcumin have been reported to
be ∼10−6 M if two curcumin molecules bind each Cu(II) and
∼10−5 M in 1:1 complexes.902 Thus, as for EGCG, competitive
1:1 MPAC function is unlikely also for curcumin. However,
despite the large Cu(II) Kd curcumin may bind directly to the
amyloid, thereby modifying its conformation and preventing
oligomerization,901 although the molecular details of such
inhibition need to be further explored.
Absent direct competitive binding or modifying interaction
with amyloids, the beneﬁts may also arise from targeting the
expanded free pools of Cu2+ (subject to Fenton toxicity) and
Zn2+ (possibly to reduce regulatory zinc levels) or very weakly
bound metal ions, for example, in APP (Kd for zinc site ∼10−6
M288). By targeting these free pools, curcumin may function
upstream from amyloid production. Curcumin has been
reported to suppress presenilin expression and inhibit Aβ40/
42 formation,903 apparently with IC50 values smaller than ∼5
μg/mL.904 Crystal structures of curcumin binding to segments
of tau protein have also been recently reported.108 Other
researchers have found that curcumin enhances macrophage
consumption and clearance of amyloids,905−907 and curcumin
will reduce any heavy-metal toxicity in the neurons.908 These
beneﬁcial eﬀects of curcumin may partly explain why
inhabitants of rural Northern India have some of the world’s
lowest age-corrected AD incidences.866
New curcumin-derivatives are among the many metal
chelators currently being optimized for AD treatment,445,909
and at least 10 patents have been ﬁled in the last couple of years
regarding curcumin or its derivatives in AD treatment (See
Table 1).
Melatonin is a BBB-penetrable hormone involved in
maintaining the circadian rhythm and hippocampus memory
formation910 (see Figure 14). While the day concentration is 10
times higher than at night in young individuals, the diﬀerence
can almost disappear in older people due to reduced melatonin
production.911 Melatonin’s antioxidant,912,913 anti-inﬂamma-
tory,914,915 and antiapoptotic eﬀects on neurological disorders
are well-documented,916−919 while therapeutic potential is also
large due to low toxicity.920
Figure 14. (Pseudo)natural antioxidants with metal-chelator function under investigation for treatment of AD.
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Table 1. Patents Addressing Disease-Modifying Treatments of AD Based on the Metal Ion Hypothesis
active substance(s) hypothesis strategy patent number filing date
Chelators
clioquinol clioquinol is effective against AD antiamyloidosis by clioquinol, B12
(+carrier)
US 6,001,852 2/1998
various metal chelators metal chelation can resolvate amyloids,
enhance clearance
chelators against AD US 6,323,218 B1 3/1998
bathocuproine/indomethacin metal chelation can resolvate amyloids,
enhance clearance
chelators against AD US 7,045,531 B1 3/1998
lipophilic diesters of metal chelators antioxidant metal chelators against
neurological disorders
chelators against neurological disorders,
including AD
US 6,458,837 B1 9/1998
1,10-phenanthroline complexes metal chelation can resolvate amyloids,
enhance clearance
chelators against AD US 7,704,987 B1;
WO 01/07442
7/2000
deferoxamine (DFO) metal chelators against neurological
disorders
DFO against neurodegeneration caused
by ischemia
US 7,618,615 B2 8/2005
phenolic compounds antioxidant metal chelators against
neurological disorders
antioxidant chelators against neurological
disorders, including AD
US 2003/0236202 4/2003
N-alkyl N-phenylhydroxylamine
chelators
metal chelation can resolvate amyloids,
enhance clearance
chelators against AD, PD, stroke US 2003/0225087 6/2003
8-hydroxy quinoline derivatives metal chelation can resolvate amyloids,
enhance clearance
chelators against neurological disorders,
inclunding AD
US 2006/0089380 7/2003
clioquinol derivatives metal chelation can resolvate amyloids,
enhance clearance
chelators against AD US 2006/0167000 10/2003
metal chelators Zn chelation can modulate APP modulate interaction between metals and
APP
US 2004/0265847 11/2003
amyloid-binding metal chelators metal chelators can resolve amyloids dual function, amyloid binding−metal
chelating
US 2004/0204344 6/2004
N-containing polycyclic chelators metal chelation can resolvate amyloids,
enhance clearance
chelators against neurological disorders,
including AD
US 2007/0185072 3/2004
clioquinol clioquinol is effective against AD antiamyloidosis, possibly formulated with
B12
US 2006/0074104 4/2005
polyquinoline derivatives metal chelation can resolvate amyloids,
enhance clearance
chelators against neurological disorders,
including AD
US 2009/0227626 8/2006
deferoxamine (DFO) metal chelators against neurological
disorders
nasal administration of DFO against
neurological disorders
US 7,776,312 B2 10/2006
8-hydroxyquinoline derivatives metal chelation can resolvate amyloids,
enhance clearance
antiamyloidosis for neurological disorders
including AD
US 2008/0161353 9/2007
various metal chelators metal chelation can resolvate amyloids,
enhance clearance
chelators against neurological disorders,
including AD
US 2009/0233893 5/2007
multifunctional ring-containing
chelators
antioxidant metal chelators against neurol.
disorders
orally administered against neurological
disorders, including AD
US 2009/0105269 9/2008
chelating agents antioxidant metal chelators against
neurological disorders
chelators against neurological disorders,
including AD
US 2010/0234338 3/2009
deferoxamine (DFO) metal chelators against neurological
disorders
nasal administration of DFO against
neurological disorders
US 2010/0267834 7/2010
MT Derivatives
MT MT dysfunction leads to neurological
disorders
direct MT to neuron to restore free/
bound zinc and copper balances
WO 03/105910 A1 6/2003
MT-derived peptides MT dysfunction leads to neurological
disorders
MT peptide fragments as MPACs or for
rebalancing the free/bound zinc pools
US 2010/0166759 2/2007
modified, selenium-containing MTs MT dysfunction leads to neurological
disorders
modified MTs formulated to higher
efficiency than MTs
US 2009/0318333 3/2007
antioxidant X-Cys-X-Cys-X peptides antioxidant metal chelators against
neurological disorders
chelators against neurological disorders,
including AD
US 2011/0190195 4/2011
Dietary Cocktails
zinc, vitamin C/E/B6, selenium,
gluthathione, various amino acids
autism combination treatment based on MT
dysfunction hypothesis
MT promotion by dietary coctail of
vitamins and amino acids
US 7,534,450 B2 5/2007
turmeric (curcuminoids), EGCG,
lipoic acid, B12, vitamin C/E, etc.
AD combination treatment against oxidative
stress, Aβ, inflammation, and glycation
coctail of natural ingredients targeting
several or all mentioned pathways
US 2009/0143433 12/2008
Curcuminoids
turmeric extract/curcuminoids turmeric extracts reduce amyloid more than
curcumin
formulation of tumeric extract against AD US 2010/0098788 10/2009
curcumin−cyclodextrin curcumin−-cyclodextrin is more effective
than curcumin
curcumin−cyclodextrin administration to
AD patient
US 2010/0179103 6/2009
curcumin prodrug derivatives intranasal administration enhances curcumin
effect
curcumin is administered intranasally to
AD brains
US 2008/0076821 4/2007
heterocyclic compounds heterocyclic compounds may inhibit Aβ
deposition
AD treatment by oral dose of drug can
delay AD
US 2008/0103158 10/2007
curcuminoid bioavailable curcuminoids may be efficient
against AD
curcuminoid, antioxidant, and carrier
formulation
US 2009/0324703 3/2007
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In AD patients, the melatonin levels are further reduced
compared with same-age healthy individuals.921,922 Early sleep
disorders have been associated with AD, possibly indicating a
common underlying etiology,923 and light therapy may work924
against AD-associated sleep disorder.925 Melatonin may counter
cognitive impairment,926,927 and on the molecular level, it
reduces amyloid toxicity916,919,928 and tau hyperphosphoryla-
tion929−931 and may thus be eﬃcient against AD although the
molecular mechanisms are unknown.932−934
Melatonin contains an amide functional group connected to
two rotatable C−C bonds, providing potential ﬂexibility to
chelate Cu(II) and Zn(II), and chelation has been observed
experimentally.935 Melatonin may work as a metal chelator
when inhibiting formation of soluble Cu(II)− and Zn(II)−
amyloid oligomers.936,937 Melatonin’s antioxidant activity
against Aβ-induced ROS may protect cultured neurons938
and protect mitochondria of Alzheimer models of mice.939
Recent work suggests that melatonin may induce heme
oxygenase known to be down-regulated in AD and thus help
restore iron/heme homeostasis, see section 4.8.940 Melatonin
also functions as an antioxidant in ALS,941 probably scavenging
superoxide (O2
−) in absence of functional SOD, in the same
way it scavenges superoxide generated by amyloids.912
Melatonin also protects neurons from Hg toxicity,829 but
whether it is by scavenging of ROS or by metal chelation is
unknown. Of special interest in future developments are
melatonin derivatives with improved antioxidant capabilities
such as tacrine−melatonin hybrids.942,943
Galantamine, for example found in the Caucasian snowdrop
(Galanthus caucasicus), has been used against neurological
symptoms in the Soviet Union at least since the 1950s.944 The
compound is a potent acetylcholinesterase inhibitor,945,946
approved by the FDA for AD treatment, showing beneﬁcial
eﬀects on learning and memory947,948 with a safety proﬁle
resembling that of synthetic acetylcholinesterase inhibitors
currently on the market.949 Importantly, galantamine has been
found to be more potent and suggested to work via more
mechanisms than synthetic inhibitors.950 Stimulation of Aβ
phagocytosis was recently suggested as a second mechanism for
galantamine, which could possibly explain these observa-
tions.951 Thus, this compound would be an example of a
dual-function treatment targeting both acetylcholinesterase and
Aβ clearance and is sold under the trade name Razadyne.65
A plausible mechanism of action of natural antioxidant BBB-
penetrable metal chelators in enhancing α-secretase activity
may be chelation of free inhibitory divalent metal ions, reducing
the pool of Cu2+/Zn2+ bound in the APP α-splicing
region,67,288 since the Kd's (∼10−6 M) are too small for
MPAC function (Kd < 10
−8 M). A second possibility is that
they prevent a ROS-producing toxic mode of free metal ions or
amyloids, thus reducing oxidative stress, which could also
improve amyloid balance, as explained in section 5.
12. COMBINING THE HYPOTHESES: A BIOINORGANIC
VIEW OF ALZHEIMER’S DISEASE
12.1. Dysfunction of Proteins Involved in Metal
Homeostasis: MT as an Example
AD is a complex disorder with genetic, environmental, and
lifestyle-related risk factors, with distinct pathological features,
and with age as a substantial trigger. Because of this, any
pathogenic theory of AD needs to not only explain the many
risk factors and beneﬁcial factors but also explain how the aging
brain becomes a target of AD as a function of these risk factors.
Furthermore, although Aβ oligomers are neurotoxic and their
hydrophobicity correlates with oligomerization and membrane
interaction abilities as well as toxicity,239 it is not currently clear
whether such toxicity is the cause of neurodegeneration in AD,
for example, via signaling of apoptosis by Aβ binding to
mitochondrial alcohol dehydrogenase,498 and if so, whether it
implicates metal ions only in the formation or as actual
constituents of these toxic forms or whether amyloid toxicity is
secondary to underlying gradual dyshomeostasis that would
suggest Fenton toxicity or regulatory protein dysfunction (e.g.,
loss of metalloprotein function by functional metal ion
deﬁciency due to reduced bound natural metal pools) as
primary toxic modes.
The role of metal ions in deﬁning AD etiology is rapidly
emerging,11,12,25,68,141 and the metal ion hypothesis can, as
described, explain most pathological features and risk factors
linked to AD, although much remains to be established. In
particular, as has been the focus of this review, zinc
homeostasis, the balance between the free Zn2+ and bound
Zn(II) pools, aﬀects all the pathways known to be closely
associated with AD, including the two hallmark molecular
features, amyloidogenesis and tau pathology. Dyshomeostasis
of metal ions occurs mainly within those areas of the brain
(hippocampus, cerebral cortex10,166,311) where Aβ accumulates
and AD ﬁrst sets in.384,952 The amyloid cascade hypothesis, in
contrast, does not currently in itself explain the localized Aβ
accumulation, because Aβ is produced throughout the brain.8,79
However, in terms of zinc homeostasis, it is natural that AD
progresses from the ZEN and astrocytes in the cerebral cortex.
As discussed in this review, disturbed zinc homeostasis
occurs via dysfunctional ZnTs, MTs, or ZIP transporters.10,144
Genetic errors or polymorphisms can contribute to changes in
zinc binding aﬃnity of these proteins or change their
production−clearance balances and may gradually change the
Zn(II)/Zn2+ balance in ZEN and astrocytes that maintain CNS
homeostasis and thus express most of the MT-3.535,953
Furthermore, post-translational modiﬁcations from, for exam-
ple, oxidative stress or exogenous exposure may impair the
Table 1. continued
active substance(s) hypothesis strategy patent number filing date
Curcuminoids
curcumin derivatives curcumin reduces Aβ burden and oxidative
stress in AD
bioavailable curcumin derivatives US 2006/0060644 6/2006
curcumin derivatives curcumin reduces Aβ burden and oxidative
stress in AD
curcumin derivatives inhibit plaque
formation
US 2010/0087527 9/2009
curcumin nanoparticles formulation of curcumin that enhances
bioavailability
curcumin nanoparticles against AD,
cancer, etc.
US 2011/0190399 7/2009
methylene blue curcumin analog formulation of curcumin that enhances
bioavailability
curcumin methylene blue against AD US 7,906,643 2/2010
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function, stability, and clearance of these metalloproteins
directly. For example, ROS exposure leads to increased free
Zn2+ pools in normal astrocytes but not in MT-3-null
astrocytes.954
The hypothesis that dysfunctional or insuﬃcient MT is a
partial cause of AD, leading to increased free [Zn2+], partly
retained in vesicles,170 lack of neuromodulation, and free Zn2+-
induced amyloid aggregation, was ﬁrst put forward by Bush.68 It
has been accompanied by other theories of MT dysfunction as
a central cause of zinc imbalances in ALS.701,712 Zinc
dyshomeostasis is a plausible underlying pathogenic cause of
age- and AD-related biochemical changes which is simple and
has broad explanatory power and can explain the failure of
antiamyloid drugs that target only one of many zinc proteases
involved in Aβ imbalance.65,136,137
Age-correlated impairment of zinc homeostasis most likely
contributes to senescence.955 Zinc dyshomeostasis and MT
suppression are correlated with telomere shortening,643 and
free Zn2+ is an underlying regulator or active site ingredient of
most of the proteins discussed in this review, including the zinc
proteases that control the amyloid production−clearance
balance. Expression of inﬂammatory interleukins (IL) and
MT-1/MT-2 increases with age and AD.956
Astrocytes maintain brain homeostasis by expressing MTs,
SOD-1 and SOD-3, and amyloid-degrading metalloproteases,94
and have been implicated as dysfunctional in neurological
disorders.428,429 MT-3 plays little role in oxidative-stress/
inﬂammation but an important role in zinc and copper
homeostasis and cell regeneration, whereas MT-1/MT-2 are
antioxidants in particular in the astrocytes535 (this is probably
why MT-1/MT-2 deﬁcient mice are less resistant to ALS
induced by G93A mutations in Cu,Zn-SOD957,958). MT-3
dysfunction will necessarily disturb zinc and copper homeo-
stasis, impairing astrocyte and ZEN function.10,144
Nasally administrated Hg,959,960 Mn,961 or other metals962
may accumulate in the brain and induce and bind to
MT,316,963,964 and thiophilic metals such as Hg(II) easily
substitute Zn(II) in MT.965,966 This enhances the free Zn2+
pool and reduces the bound Zn(II) pool, while the remaining
Zn−S bonds are perturbed, most likely to the eﬀect of altering
the Kd's that are essential for MT’s buﬀering function.
967
Various stress inducers such as ROS and exogenous metals
perturb zinc homeostasis via MT.260 The abnormal MT
expression in AD580,592,535 may in part be related to such
insults to the CNS,441,968,969 although stress-induced inter-
leukins,539,551 glucocorticoids,541,552,553 and oxidative stress555
possibly from other pathogenic events also induce MTs
separately. If MTs become dysfunctional, it is plausible that
astrocyte homeostatic capabilities are substantially reduced.
One seemingly paradoxical observation is Cu- and Zn-
proﬁle-based monitoring of MT-1/MT-2 showing reduced
protein levels in AD, where other researchers have observed
elevated levels with nonmetal-probing methods,592,593 and the
study also revealed that MTs in AD brains are more oxidized
than in healthy brains.970 This is however consistent with MTs
being monitored that have lost their metal ions, that is, oxidized
thionein apoproteins that may be dysfunctional,535 consistent
with the view presented here that metal ion dyshomeostasis is
essentially a shift from bound M(II) to free M2+ pools. Also,
expression of MT-3 is periodical upon neuronal insults and may
decrease in proportion to degeneration of ZEN or astrocytes,591
whereas the resulting free Zn2+ and inﬂammation will induce
MT-1 and MT-2 in remaining neurons.971 Free Zn2+ in
extracellular space may potentially lead to amyloid forma-
tion,176,179,183,184 and arrest of Zn2+ in synaptic vesicles may
impair neuromodulation by Zn2+.261,262,266 Furthermore,
caspases, important mediators of apoptosis, the end stage of
neurodegeneration, are induced if Zn(II) is not available in
intracellular metalloproteins.972
MT dysfunction may cause tau hyperphosphorylation, a
pathological feature of AD shared by other neurodegenerative
diseases that all pathogenic models should explain: If MT
cannot transfer Zn(II) to zinc-ﬁngers, MSOT (mammalian
suppresor-of-tau pathology) could be dysregulated, which could
disturb tau phosphorylation balance.973 Alternatively, the
elevated free Zn2+ may directly enhance hyperphosphorylation
of tau and release it from microtubules.974 Recently it was
shown that free Zn2+ causes tau phosphorylation via activation
of kinase pathways (MAPK/ERK).975
A rationale for observed α-secretase enhancing function of
antioxidant chelators such as curcumin, EGCG, and lipoic acid
is their free-metal chelating function that may clear free metal
ions, thus reducing the burden of excessive free inhibitory Zn2+
in regulatory sites such as in the APP α-secretase cleavage
region. This is also more consistent with their relatively weak
metal-binding properties (Kd ≈ 10−6 M), which are not
suﬃcient to competitively strip Cu(II) and Zn(II) from Aβ−
metal complexes (Kd < 10
−8 M) as MTs can. This would
suggest a new focus on targeting regulatory metal ions in APP
instead of amyloids directly as is normally sought with MPACs.
12.2. Converging toward Apoptosis
Apoptosis is a necessary process of CNS development, and its
disturbance can cause mental disorders.729 The intrinsic
mitochondrial pathway of apoptosis,976 if triggered by metal
dyshomeostasis, seems to combine many of the pathological
features observed in neurological disorders.916 Apoptosis is
most likely triggered when the mitochondria are insulted by
further direct stress leading to shutdown of the respiratory
chain and expulsion of cytochrome c, an iron/heme-containing
protein complex that is an integral part of respiratory chain, as
an early suicide event.13,487 This then leads to caspase-mediated
apoptosis and mitochondrial membrane permeability governed
by apoE transport proteins and Ca2+ concentration.911 Before
that threshold, conditions may worsen gradually, as in MCI.
The gradual buildup of stress followed by triggering events has
been emphasized in relation to oxidative stress as an early cause
of AD.491
ApoE, which transports cholesterol to mitochondria, is highly
concentrated in astrocytes,977 and impaired transport to
mitochondria due to toxic exposure or mutations in ApoE
might set an earlier stage for stress-induced apoptosis, thus
increasing risk of triggering AD. Mitochondrial dysfunction in
astrocytes due to apolipoprotein mutations may therefore be a
rationale for understanding these genetic risk factors.
The fundamental role of Zn(II)/MT in preventing
apoptosis539,972 is evident from the research into zinc-
dependent (class I, IIa, IIb, and IV) histone deacetylases that
prevent apoptosis. The corresponding histone deacetylase
inhibitors that are currently being developed as apoptosis-
inducing cancer treatments978 are eﬃcient zinc chelators and,
consistent with the ﬁndings presented in this review, show
promising use as treatments of neurodegenerative diseases.979
Cytochrome c release and other symptoms of neuronal
apoptosis in experimental stroke models can be inhibited not
only by melatonin980,981 but also the carbonic anhydrase
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inhibitor methazolamide.982 This compound contains signiﬁ-
cant metal chelator functions, in particular with sulfonamide
groups, which have been shown to coordinate Zn(II).983,984
The most widely used treatment of AD is currently still
acetylcholinesterase inhibitors such as donepezil and tacrine.860
However, underlying causes of the acetylcholine neuro-
transmitter shortage, which leads to cognitive decline,62 must
be described in a uniﬁed view of AD. The most obvious
explanation for acetylcholine deﬁciency in AD according to the
MT/Zn dysfunction hypothesis is that free Zn2+ inhibits
choline acetyltransferase985 or pyruvate dehydrogenase, which
produces acetylcoenzyme A.986
12.3. The Zinc Cascade: An Example of Metal-Based
Etiology
From the synthesis of observations discussed above, a cyclic
pathogenic etiology can be constructed, as shown in Figure 15.
It is based on the current emerging consensus of a self-
perpetuating cascade, spiraling toward AD as the endgame of a
gradual process often spanning decades, and similar views on
AD have been suggested for calcium homeostasis,117 zinc and
calcium dyshomeostasis,354 and oxidative stress.88 The
signiﬁcance of each input is not yet well-established and may
be the subject of future investigation. It is a theory based on a
collection of all observations discussed in this review and as
such a minimal model that will need to be corrected. The
chronology is also not absolute, as evident from the multiple
feedbacks discussed in this review. The cascade stresses the
absence of simple, linear etiologies and emphasizes, as do other
researchers,354,377,987 that a systemic model is required in order
to account for genetic, lifestyle, and environmental factors as
they progress over time and lead to AD, possibly after crossing
critical thresholds in, for example, ROS levels,491 Aβ
concentrations, or free metal concentrations such as Zn2+,
Ca2+, or Fe2+.354,377 A spiral etiology has been suggested from
studies in calcium dyshomeostasis117 and a positive feedback
loop between oxidative stress and the amyloid cascade also
supports the cyclic model.88,508 The model does not provide
any weight of importance to any of the steps; these weights will
hopefully be determined in the future. The AD stage can be
envisioned in the center of the model, with mild cognitive
impairment and preclinical phases approximately correlating
with pathologies of the outer circle in Figure 15.
(1) There is a genetic background to AD: Mutations related
to Aβ balance, metabolism, immune defense, or stress-
response, including metal homeostasis, may impair the
robustness of the homeostatic system, notably in
astrocytes, reducing resistance to post-translational
modiﬁcations from later stress-inducing events.48−52
Calcium homeostasis was the ﬁrst established genetic
risk factor relating directly to metals via presenilin,368,369
although recently, presenilin was also linked to copper
and zinc transport.154 Genetic risk relating to APP
processing may aﬀect metal dyshomeostasis via APP’s
ferroxidase function and Zn2+- and Cu2+-regulatory
sites.290 Various genetic risk factors become active at
various stages of life, some possibly during early CNS
development729 (presenilin may have a role in fetal
neurogenesis988) and some from later brain trauma7 or
chemical exposure41−43,47 and may lead to initiation of
the spiral cascade in Figure 15.4,32
(2) Life-style-related risk factors such as antioxidant
deﬁciency,55 obesity,35,36 hypercholesterolemia,39,40 pas-
sivity,57,61,56 and smoking34,772 may aggravate these risk
factors by challenging metabolic networks, the already
weakened stress response, and overall neuronal capacity.
They all relate to metal ion dyshomeostasis, notably via
zinc, as discussed in section 7. Long-term stress
associated with an unhealthy life style may gradually
Figure 15. A bioinorganic view of Alzheimer’s disease progression, with a focus on zinc and copper, reconciling the amyloid cascade hypothesis (as
seen when starting from the upper right) with the oxidative stress (upper left) and metal ion hypotheses. Risk factors are colored in red, beneﬁcial
factors are colored in cyan-blue. A possible causal relationship to iron dyshomeostasis via the ferroxidases, ceruloplasmin, and APP is given in the
text.
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reduce mitochondrial eﬃciency and stress response, as
implied by the increased expression of stress-related
proteins during senescence,629 thus increasing risk of
AD.13,71,72,486,487
(3) Long-term or event-based insults from, for example, head
trauma, smoking, or chemical exposure are known risk
factors of AD7,27,38,41 and may further weaken the stress
response via local neuronal damage, oxidative stress, and
mitochondrial ineﬃciency.63,70,357 Insults may cause
post-translational modiﬁcation (oxidation, exogenous
metal binding) of metal-homeostatic and stress-related
proteins such as SOD, ceruloplasmin, or MT and modify
amino acids binding to metal ions,568,569 for example,
nitrosative stress reducing bound Zn(II) used for transfer
to proteins.989
(4) As an example, exogenous metals (Al, Hg, Pb, Cd) may
be absorbed in the CNS,960−962 accumulated in the
spinal cord and motor neurons (ALS)818 or in the
olfactory bulb, hippocampus, and remaining cortical
brain (AD),43,959 associated with AD pathogene-
sis.10,73,384,952 Tau phosphorylation and disruption of
microtubules as well as Aβ imbalances may be aggravated
by exposure (see section 10).824,826,827,831 Soft Lewis
acids may inhibit zinc-dependent enzymes such as
MES,692 required for methylation pathways, and SAM,
leading to hyperhomocysteinemia, apoptosis, and tau
pathology,43,678 and could possibly bind the known
regulatory Zn2+ sites in APP.290 Al is instead a hard
iron(III)-mimetic Lewis acid44,731 and a risk factor in
AD44−46,730,739,741 suggested to stabilize iron-regulatory
proteins and cause elevated free iron levels and Fenton-
based oxidative stress and contribute to an “iron cascade”
also accelerating neuronal death.144,376
(5) Mutations or stress-induced post-translational modiﬁca-
tions of stress-related metalloproteins such as cerulo-
plasmin, MT, or SOD may impair protein function963,990
or even produce toxic gain of function, as in ALS.702−704
For example, Zn-MT-1/MT-2 levels in AD livers are
reduced despite brain up-regulation,594 suggesting that
MTs exported to the liver are reduced in number or
modiﬁed to bind less zinc. Many of these mutations and
modiﬁcations are currently unknown and will change the
risk and the onset of AD.
(6) Zinc dyshomeostasis is associated with AD10,11,144,148
and most likely results from mutations and modiﬁcations
of proteins involved in zinc homeostasis. Brain homeo-
stasis is governed by astrocytes, zinc homeostasis is
governed by MTs, particularly expressed by astrocytes,
and astrocytes are central cells in AD pathogenesis.429
Dysfunctional MTs would increase the free Zn2+ pool
and reduce the bound, transferable Zn(II) pool,532 thus
increasing free Zn2+ between synapses in neuro-
pils,146−148 while global zinc levels are reduced or
unchanged in the brain,152,168 due to redistribution
toward extracellular deposits. As a compensation, MT-1/
MT-2 is up-regulated by free Zn2+ and by other stress
factors527,539,541,554 as observed in AD.581,592,593,583 MT-3
regulation is initially periodic upon neuronal insult,591 as
described in section 6, and may be chronically down-
regulated in the advanced stage of AD if astrocytes, a
possible target of early pathogenesis,429 become
dysfunctional.
(7) As an example, modiﬁcations of MT may disturb the vital
balance between bound Zn(II) available for transfer to
active sites and free regulatory and vesicular Zn2+.10 The
distinction between bound and free pools of metal ions
seems essential to understand AD pathogenesis.
(A) The α-secretases (Figure 3) are membrane zinc
proteases.8,84 Lack of Zn(II) in the α-secretase
active site could be caused by impaired transfer
from MT or by mutations or post-translational
modiﬁcations that reduce Zn-binding aﬃnity. Lack
of Zn(II) will impair the nonamyloidogenic α-
secretase pathway, leading to Aβ accumulation.
(B) The equilibrium between metallic holo-SOD-1 and
holo-SOD-3 and their demetalated apoforms is
shifted toward the latter if Zn(II) is unavail-
able,957,958 leading to gain of toxic function in
some cases.273,705 This may cause ALS-like
pathogenesis, and oxidative stress in AD11,12
could partly be due to this and partly due to the
toxicity of various forms of Aβ/Cu(II)80,336,338 that
begin to accumulate as zinc moves from MT-
bound pools to free pools, since free Zn2+ is a
central inducer of amyloid oligomerization.
(C) Absence of MT-governed Zn(II) transfer to active
sites of neprilysin, insulin-degrading enzyme, and
matrix metalloproteinase, essential to degrade Aβ
extracellularly,164 decisively disrupts the Aβ
production−clearance balance.
D) Absence of Zn(II) transfer from MT to Zn(II)-
dependent MES causes disruption of methylation
pathways, hyperhomocysteinemia, and impairment
of methylation of protein phosphatase 2A, which
then increases tau phosphorylation.43,991−994
(E) Zn7-MT2 has been shown to substitute Cu(II)
with Zn(II) and prevent toxicity and aggregation
of Cu(II)−Aβ 10 times more eﬃciently than MT-
3.607 The absence of this function, normally likely
to be mediated by the astrocyte synthesis of MT-2
(which is up-regulated in AD despite the overall
neuron degeneration) could thus possibly aggra-
vate the formation of soluble Cu(II)−Aβ
oligomers involved in producing the toxic forms
of the amyloids.
(8) Free Zn2+ and Cu2+ (now no longer bound to MT) can
provide a diagnostic tool for disease progression, for
example, the Cu/MT ratio,622 and these free ions may
lead to Aβ buildup:
(A) Free Zn2+ and Cu2+ may initiate oligomerization of
Aβ, stabilize oligomers, and prevent their degra-
dation,176−182,174,189,190 thus leading to Aβ
oligomer buildup. One plausible structure−func-
tion correlation uniting many Aβ-region APP
mutations that cause familial AD (Dutch
(E22Q), Italian (E22K), Arctic (E22G), Iowa
(D23N), English (H6R), and Tottori (D7N))
with the metal ion hypothesis is the common
tendency of mutations and metal ions to neutralize
and potentially increase the hydrophobicity of the
negatively charged amyloids that may otherwise be
resistant to oligomerization.
(B) APP contains both regulatory Cu(II) and Zn(II)
sites, with Kd of ∼10−8 M339 and ∼10−6 M,288
respectively. Free Zn2+ may bind to the α-cleavage
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site of APP and prevent nonamyloidogenic α-
secretase activity, thus shifting APP cleavage
toward Aβ production, leading to further Aβ
buildup.67,288 Free Zn2+ may also inhibit APP
ferroxidase activity at this stage,290 possibly causing
functional iron deﬁciency resembling ceruloplas-
min dysfunction,410,411,422 although the chronol-
ogy of the pathogenesis of various metal ions
remains to be determined.
(C) Active site Zn(II) transferred from functional MT
allows extracellular metalloproteases to degrade
Aβ, whereas free regulatory Zn2+ instead inhibits
Aβ degradation by extracellular metalloproteases
produced by the astrocytes, notably neprilysin,
which is considered the main Aβ protease97,98
targeting both monomers and oligomers.99 This
Zn2+ inhibition may impair Aβ clearance and
leading to further Aβ buildup.94,292
(9) The excess free Zn2+ in local areas around neuropils may
lead to Zn2+-induced hyperphosporylation of tau,301 and
Zn2+ subsequently remains localized in the neuroﬁbrillar
tangles.302
(10) Disrupted zinc homeostasis and elevated free Zn2+ may
also lead to general accelerated aging processes and
apoptosis by enhancing telomere shortening641−643 or
weakening apoptosis suppression,539,972 for example, via
zinc-dependent histone deacetylases.978,979
(11) AD spreads from the cortical brain where ZEN are
present that are central to memory formation.10 These
neurons depend vitally on MT for maintaining homeo-
stasis and stress control, and dysfunctional astrocytes
(which are main producers of MT and are targets of
exogenous metal exposure820) could contribute to their
degeneration25,174 and are increasingly in focus as
primary cells involved in neurological disease.429 The
hippocampus is a main stage of AD4,8,10 and a main stage
of metal ion dyshomeostasis.10,166,311,405,536 MT-3 has
been found to reduce neurodegeneration in mouse
hippocampus.605
(12) Retainment of Zn2+ in vesicles for co-release with
glutamate disturbs neuromodulation by lack of
NMDA/GABA receptor inhibition.10,262,264,282−284 Free
Zn2+ remains in neuropils.146−148 Without Zn2+ being co-
released, glutamate is not modulated,25 causing excito-
toxicity in gluzinergic neurons located in the cerebral
cortex, in particular the limbic system.264,285 This leads to
cognitive deﬁcits, and the excess free Zn2+ ultimately
leads to neuronal necrosis and apoptosis.10,298−300 Free
Zn2+ down-regulates mitochondrial energy production,
for example, by aconitase,634,638 and inhibits cytochrome
c oxidase,635−637 the terminal Cu- and Fe-containing
protein in the respiratory chain, an example where Cu,
Zn, Fe, metabolism, and oxidative stress converge. While
free Zn2+ inhibits aconitase, MT possibly contributes to
aconitase activity by transfer of Zn(II), as observed in
mice.633
(13) Zinc dyshomeostasis, a common feature of diabetes types
I and II,647,650−653 also leads to impaired structural
integrity of insulin hexamer651,659,660 and lower glucose
utilization, causing insulin resistance.384,645 These dia-
betes-like symptoms correlate with AD because they are
both to some extent correlated by the same underlying
variable, zinc dyshomeostasis.648
(14) The elevated Aβ-oligomer concentration induced by the
growing free Zn2+ pool adds to the neurotoxic cascade by
interfering with the mitochondria and further impairing
energy metabolism,122,123,125 reducing the ability to
retain the ion gradients. Possibly, this (as claimed by
the amyloid cascade) is a critical trigger of self-
perpetuating pathogenic cycle (Figure 15), that is,
further ROS generation, MT dysfunction, elevated free
Zn2+ and depressed bound Zn(II), further amyloid
imbalance, further mitochondrial insult, and further ROS
generation. A threshold or trigger succeeded by
accelerated pathogenesis may explain the rapid disease
progression of AD.
12.4. Further Comments on the Pathogenesis
The zinc cascade presented above is not complete, and while
the individual facts are settled, their causal relationships are
currently hypothetical. Also, the zinc cascade is not complete
because cascades relating to, for example, copper, iron, and
oxidative stress have been down-played but must be
incorporated for completeness. Together, the metal ion
hypothesis, as exampliﬁed by the zinc cascade above, may
explain why one-dimensional treatments such as antiamyloid
drugs have so far been of limited use in AD therapy,65,136 since
they do not aﬀect the underlying pathogenic pathways
described.
During aging, one may say that the organism faces a metal-
homeostatic challenge relating to increased free metal ion pools
that provide oxidative stress and metabolic challenges to the
mitochondria. Given zinc’s essential role in controlling
apoptosis, telomere shortening, mitochrondrial energy produc-
tion, and transcription via zinc-ﬁngers, zinc is likely to be a
central player in aging processes, and its dyshomeostasis would
disturb these processes. The zinc cascade is an example of a
minimal model that could explain in a systemic way genetic,
lifestyle, and environmental risk factors and the pathological
changes observed in AD and reconcile it with the accelerated
aging concepts. As a minimal model, it requires expansion and
further justiﬁcation, and certain steps are likely to be less
relevant than others. Some of the possible implications are
collected in Tables 2 and 3, showing genetic and lifestyle/
exogenous risk factors and their possible, hypothetical relations
to metal ion homeostasis. Any future more reﬁned theory of
AD pathogenesis should probably attempt to account for many
of these risk factors as well.
Other cascades arising, for example, from copper and iron
dyshomeostasis will display pathogenic features that overlap
substantially with each other and with the zinc cascade
described above, for example, via Cu,Zn-MT-3, multicopper
Fe2+-oxidizing ceruloplasmin, Cu- and Fe-containing cyto-
chrome c oxidase, and Cu,Zn-SOD-1. Dysfunctional metal-
loproteins caused by mutations or post-translational modiﬁca-
tions that impair Kd's by modifying the metal binding sites may
be key targets in neurodegeneration, but whether any of the
three metals, Fe, Cu, or Zn, is more fundamental in causing
dyshomeostasis is unclear, but the consequence of enhanced
free metal pools should be the same, as also discussed with
respect to iron.377 Also, the various metal ions display diﬀerent
pathways of amyloid oligomerization and ﬁbrillation.755 It
should be a key goal in future research to resolve these metal
ion cascades in time and space and to unite genetic risk factors
with environmental and lifestyle risk factors in a systemic model
that can explain both the familial and the sporadic cases of the
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disease, with explanatory power for as many pathological
observations as possible. The zinc cascade is merely a beginning
in this context.
As the central protein of AD, APP has recently been found to
possess ferroxidase function similar to ceruloplasmin that is
inhibited by free Zn2+,290 this provides a possible connection
between the metal cascades and the amyloid cascade that could
also explain the decreased transferrin levels observed in AD.388
Since APP is located in the mitochondrial membranes and is a
ferroxidase, APP may control iron(III) import into neuron
mitochondria, perhaps in concert with APP cleavage and other
functions. Zinc appears to control both this function and the α-
secretase turnover. Impairment of the ferroxidase function by
zinc dyshomeostasis could thus suggest that amyloid imbalance
is a consequence of impaired ferroxidase function in APP. Such
a concept could put APP as the director of mitochondrial
energy metabolism by importing iron(III) for respiration,
uniting the amyloid cascade with the iron and oxidative stress
cascades, as well as the zinc cascade, via the regulatory role of
Zn2+ on both APP ferroxidase activity and α-secretase activity.
13. CONCLUDING REMARKS: TEN FOCAL POINTS OF
FUTURE RESEARCH
AD, the major form of dementia, is one of mankind’s grand
challenges, a devastating disease aﬀecting millions of people and
their families, and a substantial and growing burden to society,
with prevalence increasing rapidly.1,3,4 Because the pathogenic
mechanism of AD is poorly understood, current treatments are
mainly symptom-relieving and are at best eﬀective for up to a
year.18,53
The role of metals such as copper, iron, calcium, and zinc in
AD has dramatically expanded over the last deca-
des.10−12,14,17,68,144,145,147,159 A large number of research groups
are devoted to an understanding of the underlying biochemical
causes of AD, and most of these involve pathways that are
governed by regulatory or catalytic metal sites. In addition,
most known environmental and lifestyle risk factors of AD can
be related to underlying biochemical processes that directly rely
on metal ions, as described in this review.
The role of metal dyshomeostasis is also emerging with
respect to other neurological disorders, which are closely
associated with metal ion-controlled structural and functional
integrity of proteins such as APP, prion protein, α-synuclein,
and SOD-1, and in terms of AD, speciﬁcally APP, Aβ, a large
range of zinc-dependent proteases involved in Aβ production
and clearance, and underlying metal-homeostatic proteins,
notably MTs, which have been described in this review.
Because of this emerging paradigm shift, the vibrant ﬁeld of
bioinorganic chemistry may now have a unique opportunity to
interact with the enigmatic and immensely complex research in
neurological disorders. Hopefully, bioinorganic chemists will
take up the challenge. This review has attempted to provide a
ﬁrst encounter between the ﬁelds.
Some of the most interesting focal points of future AD
research on the interface between bioinorganic chemistry and
neuroscience are described in the following:
1. Metal ion locations in time and space during AD
pathogenesis. A clear consensus should be established
regarding the free and bound pools of Zn, Cu, and Fe in
various parts of the brain as a function of disease
progression, to remove current uncertainties in this
regard,152 because the redistribution from bound to free
pools seems to be critical in disease progression. An
understanding should be achieved of how these metal ion
imbalances aﬀect APP processing, Aβ production−
clearance balance, and molecular toxicity at various
stages of AD.
2. Risk factors and metal homeostasis. A speciﬁc focal point
of mechanistic understanding is genetic, lifestyle, and
environmental causes of metal ion dyshomeostasis and
how these relate etiologically to other pathological
features such as oxidative stress, Aβ imbalance, and tau
hyperphosporylation. Is sporadic AD a spiral etiology of
all these risk factors, together increasing total risk of AD
as age progresses, or are there critical thresholds and
turning points? Homeostasis should be further explored,
for example, via metallothioneins, prion proteins, copper
and zinc transporters, iron regulatory proteins, cerulo-
plasmin, divalent metal transporter 1,383 and heme
oxygenases, with a focus on understanding how genetic
weaknesses or stress-induced post-translational modiﬁ-
cations impair the functions of these proteins.
3. APP-regulating chelators. A third focal point of future
therapies could be the use of coordination chemistry
expertise in the design of new α-secretase enhancers and
β/γ-secretase inhibitors that protect the regulatory zinc
and copper sites in APP to restore the nonamyloidogenic
pathway. Given the relatively large Kd's of natural
antioxidant chelators, it is plausible that EGCG,
curcumin, and lipoic acid enhance α-secretase activ-
ity874,892,894 by stripping excess Zn2+ from α-secretase-
regulatory APP sites or bind excessive free Zn2+
accumulated by zinc dyshomeostasis, which inhibit APP
ferroxidase activity and thus potentially cause iron
dyshomeostasis and metabolic disruption in neuronal
mitochondria. While some of these ideas for future AD
prevention have been recently discussed,447 having zinc
and copper regulatory sites in APP as speciﬁc targets has
not yet been pursued.
4. Metal−protein-attenuating compounds. A fourth focal
point would be the clinical development of new metal
chelators, which can either target the Cu(II) and Zn(II)
amyloid oligomers directly to enable subsequent
degradation by, for example, neprilysin, which is also
Zn(II)-dependent, or target free metal ions that induce
amyloidosis. Current development of chelators such as
clioquinol has been somewhat disappointing, and more
knowledge is required,995 because metal chelation
constitutes a risky perturbation of the CNS. Too strong
chelators may be dangerous because they can strip active
sites and normal regulatory sites of their metal ions; thus
they should be designed with appropriate and selective
binding in mind, with key dissociation constants for such
designs discussed in this review. The history of
clioquinol, notably the SMON outbreak in Japan,
showed the risks associated with large doses of metal
chelators. One of several toxic modes of Aβ possibly
relates to its stripping of Cu from prion protein to
disrupt NMDA receptors and Ca2+ signaling,119 and
possibly, the large amount of copper, iron, and zinc
found in amyloid plaques derive from proteins that have
lost their function during the AD pathogenesis.
5. Oligomerization inhibitors. A ﬁfth, related focal point
would be preferential stabilization of innocent, non-
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oligomeric complexes involved in metal−amyloid inter-
action mechanisms.195 Such a strategy would include
development of Cu−Aβ transition state (de)stabilizing
molecules that either lower the barrier for formation of
innocent Aβ−Cu−Aβ species or enlarge the barrier for
the competing oligomerization steps. All approaches
mentioned in 3−5 rely on the conscious design of
adequate BBB-penetrable, drug-like metal chelators
exhibiting Kd's in the correct ranges (in the 10
−10 M
range) with emphasis on selectivity between Cu, Zn, and
Fe, depending on the target. For example, Zn(II) will
often bind ∼100 times more weakly than Cu(II) in 1:1
ratios as seen in amyloids and various relevant proteins,
and a balance between soft and hard ligands may aid
toward obtaining optimal selectivity while preventing
stripping bound Zn(II) and Cu(II) from active sites of
key proteins.
6. Bioinorganic diagnosis. The bioinorganic chemistry of
AD may also substantially contribute to new, eﬃcient,
and unambiguous diagnosis, given that amyloid load is a
poor marker for progression, and blood protein markers
may be feasible.996,997 Eﬃcient biomarkers that detect
AD in the preclinical phase could markedly improve
treatment.26 Current markers include absolute levels of
Aβ42 in the cerebrospinal ﬂuid (decreased in AD) and
overall amyloid retention in the brain (increased in AD),
tau protein levels in the cerebrospinal ﬂuid (increased in
AD), structural evidence for neurodegeneration from
magnetic resonance imaging, and, as seen in other
neurodegenerative diseases, impaired glucose (ﬂuoro-
deoxyglucose) uptake probably due to impaired
mitochondrial function.9 Biomarkers may be ranked
according to their diagnostic accuracy and ability to
provide early diagnosis, suggesting that Aβ markers rank
above tau protein markers.6,9 The same logic might be
applied to markers of free vs bound metal ion pools.
Literature examples include iron heme pools as a
marker,387 MT levels as a marker,600 or the ratio of Cu
to MT or ceruloplasmin that may monitor AD
progression.622 Given the ﬁndings reviewed here, one
might suggest to investigate any combination of the local
ratios between Fe, Zn, Cu, ceruloplasmin, heme oxygen-
ase, and MT levels together with oxidative stress markers,
APP or secretase levels, and Aβ42/Aβ40 ratios.100 Ratios
are likely to be less sensitive to individual variation and
better reﬂect de facto dyshomeostasis and may be
encouraged. Some ratios may be achieved either in
blood serum, plasma, or cerebrospinal ﬂuid, remember-
ing that disease progress correlates with local metal
redistributions from bound intracellular to free pools.
Also, as mentioned in focal point 1, marker output
should be a function of time as well as space.
7. Multifunctional antioxidants. A somewhat diﬀerent
approach is the focus on antioxidant medicine, which
can however in many cases be combined with metal
chelator function, as evident in a number of natural
antioxidant chelators.649 Also, understanding the ex-
tremely complex and wide-ranging interplay between
metal homeostasis and oxidative stress in neurological
disorders should probably be a primary objective in the
future.
8. Clear distinctions between AD and accelerated aging.
Given the similarities between various types of dementia
and geriatric depression26 and the similarities in the
underlying neurochemical changes, notably oxidative
stress and metal ion hyshomeostasis, a better under-
standing of possible critical events that trigger sporadic
AD seems warranted. A central focal point could be the
distinct diﬀerences between AD and “accelerated aging”,
for example, by comparing AD pathological features not
just to same-age controls but also to older controls. Such
research would pinpoint exactly how AD distinguishes
itself from an accelerated aged brain, for example, the
sporadic causes of the amyloid imbalance. Notably, if a
pathogenic threshold is reached, it should provide a
transition in the levels of markers that correspond to
accelerated aging, toward markers that are unique to AD.
The timing of markers is therefore crucial. The various
markers could be tested both in same-age and in older-
age controls and in AD.
9. Lifestyle and diet in relation to metal homeostasis. A
ninth focal point is the optimization of lifestyle and
dietary prevention strategies that may reduce the
nongenetic risk factors discussed in this review, which
in many cases relate directly to metal ion homeostasis or
oxidative stress.860 Importantly, we are beginning to
understand why certain diets and lifestyles are beneﬁcial
or constitute risk factors, relating to the complex
interplay between metabolism, metal homeostasis, and
oxidative stress, and this would contribute to our overall
understanding of the bioinorganic chemistry of AD.
10. Causes of the cellular origins of AD. A tenth focal point
is to identify the cellular origins of AD, where many
paths seem to converge toward a role of the impaired
zinc-enriched neurons in the parts of the brain most
aﬀected by AD, hippocampus and the astrocytes, which
maintain neuron (metal) homeostasis and are particularly
rich in metal ions and MTs. To exemplify this,
aceruloplasminemia, the neurological disease associated
with mutations in the multicopper ferroxidase cerulo-
plasmin, leads to deformation of astrocytes,998 and MT-3
can reduce neurodegeneration in mouse hippocampus.605
As will hopefully be clear from reading this review,
bioinorganic chemistry and neuroscience, while previously
considered somewhat incommensurable, will continue to
produce tremendous synergies in the future. The main goal
of such an alliance would probably be new combination
treatments that address in a systemic way several of the risk
factors and imbalances described in this review, for example,
combinations of MPACs, antioxidants, and APP modulators.
Particular emphasis might be placed on combining chelators
with aﬃnities for Fe, Cu, and Zn suitable for APP modulation
and inhibition of Aβ oligomerization with simultaneous
antioxidant function. Such combination treatments could not
only reduce side eﬀects but in fact be necessary, because other
treatments addressing only one aspect of the etiology will most
likely be ineﬃcient. Thus, the impact of the bioinorganic
chemistry with a strong emphasis on structure−function
correlations, careful identiﬁcation of key targets, and a systemic
approach to underlying pathways as attempted here could be
game-changing and may hopefully help to improve the
prospects for the millions of people suﬀering from this terrible
disease.
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LIST OF ABBREVIATIONS AND ACRONYMS
Aβ amyloid-β, 40- or 42-residue peptide derived from
APP; the most characteristic molecular symptom of
AD
AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
ADAM a disintegrin and metalloprotease family. Family of
proteins that include zinc proteases of the α-
secretase type
ApoE apolipoprotein E
ApoE4 isoform 4 of ApoE
APP amyloid precursor protein
ASD autism spectrum disorder
BACE-1 another acronym for β-secretase (beta-site APP
cleaving enzyme 1)
BBB blood−brain barrier
CNS central nervous system
Ctr1 copper transport protein 1
DMT-1 divalent metal transporter 1, an iron and copper
transport protein active in neurons
GABA γ-aminobutyric acid, the main inhibitory neuro-
transmitter of the CNS
GSH glutathione; an important antioxidant
GSSG glutathione disulﬁde; the oxidized dimer of GSH
containing a disulﬁde bridge
HIF hypoxia-inducible factor; transcription factor acti-
vated by hypoxia or lack of Fe and governing a large
part of the cellular response to energy input
shortage-related stress
HO-2 heme oxygenase isoform 2, a heme degrading
enzyme expressed in neurons
LRP1 lipoprotein-receptor-related protein 1, aka apolipo-
protein E receptor (APOER)
MCI mild cognitive impairment
MES methionine synthase, a cobalt (B12) enzyme
converting homocysteine to methionine of impor-
tance in neurochemistry
MPAC metal−protein-attenuating compounds
MT metallothionein; there are four main classes, MT-1,
MT-2, MT-3, and MT-4; MT-1 has many isoforms
MTF-1 metal-responsive transcription factor-1
NMDA N-methyl-D-aspartate, an amino acid neurotransmit-
ter agonist working on glutamate-dependent
receptors of the NMDA-R type
NMDA-R N-methyl-D-aspartate receptor, a class of glutamate
receptors that are aﬀected by NMDA
RNS reactive nitrogen species, for example, nitric oxide,
NO•
ROS reactive oxygen species, for example, H2O2, O2
−,
HO•
SAM S-adenosyl methionine, a central molecule in the
methyl transfer system (the SAM Cycle) and in
neurochemistry; AD is associated with low SAM
levels
sAPPα secreted, soluble amyloid precursor protein, a
nonamyloidogenic peptide fragment derived from
APP by cleavage of the α-site by α-secretase
SOD superoxide dismutase; there are three forms in
humans, intracellular SOD-1, containing Cu and
Zn, SOD-2, containing Fe or Mn, and extracellular
SOD-3, containing Cu and Zn
STAT3 signal transducer and activator of transcription 3;
transcription factor involved in cell growth and
apoptosis
ZEN zinc-enriched neurons; glutamatergic neurons that
co-release Zn2+ from synaptic vesicles to modulate
neurotransmission
ZIP a family of zinc-transporter proteins, important for
controlling the free Zn2+ pool
ZnT a family of zinc-transporter proteins; transports
Zn2+ into synaptic vesicles of ZEN
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(246) Damante, C. A.; Ösz, K.; Nagy, Z.; Grasso, G.; Pappalardo, G.;
Rizzarelli, E.; Sov́aǵo,́ I. Inorg. Chem. 2011, 50, 5342.
(247) Meloni, G.; Sonois, V.; Delaine, T.; Guilloreau, L.; Gillet, A.;
Teissie, J.; Faller, P.; Vasak, M. Nat. Chem. Biol. 2008, 4, 366.
(248) Burdick, D.; Soreghan, B.; Kwon, M.; Kosmoski, J.; Knauer,
M.; Henschen, A.; Yates, J.; Cotman, C.; Glabe, C. J. Biol. Chem. 1992,
267, 546.
(249) Hatcher, L. Q.; Hong, L.; Bush, W. D.; Carducci, T.; Simon, J.
D. J. Phys. Chem. B 2008, 112, 8160.
(250) Irving, H.; Williams, R. J. P. J. Chem. Soc. 1953, 3192.
(251) Martell, A. E.; Smith, R. M. NIST Critically Selected Stability
Constants of Metal Complexes, Database 46, Version 8.0, NIST:
Gaithersburg, MD, 2004.
(252) Drago, D.; Bettella, M.; Bolognin, S.; Cendron, L.; Scancar, J.;
Milacic, R.; Richelli, R.; Casini, A.; Messori, L.; Tagnon, G.; Zatta, P.
Int. J. Biochem. Cell Biol. 2008, 40, 731.
(253) Bush, A. I. Alzheimer Dis. Assoc. Disord. 2003, 17, 147.
(254) Atamna, H.; Frey, W. H., II Proc. Natl. Acad. Sci. U.S.A. 2004,
101, 11153.
(255) Atamna, H.; Boyle, K. Proc. Natl. Acad. Sci. U.S.A. 2006, 103,
3381.
(256) Bao, Q.; Luo, Y.; Li, W.; Sun, X.; Zhu, C.; Li, P.; Huang, Z.-X.;
Tan, X. J. Biol. Inorg. Chem. 2011, 16, 809.
(257) Atamna, H.; Frey, W. H. Mitochondrion 2007, 7, 297.
(258) Pramanik, D.; Dey, D. G. J. Am. Chem. Soc. 2011, 133, 81.
(259) Atamna, H.; Frey, W. H.; Ko, N. Arch. Biochem. Biophys. 2009,
487, 59.
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Herrmann, M.; Renard, P.; Brockhaus, M.; Hock, C. J. Neurochem.
2000, 74, 231.
(830) Yano, K.; Hirosawa, N.; Sakamoto, Y.; Katayama, H.;
Moriguchi, T. Toxicol. Lett. 2003, 144, S134.
(831) Cedrola, S.; Guzzi, G.; Ferrari, D.; Gritti, A.; Vescovi, A. L.;
Pendergrass, J. C.; La Porta, C. A. FASEB J. 2003, 17, 869.
(832) Osredkar, J.; Zenko, B.; Grum, D. K.; Krsnik, M.; Dzeroski, S.;
Horvat, M.; Kobal, A. B. Metod Zvezki 2005, 2, 161.
(833) Rao, M. V.; Purohit, A. R.; Patel, T. A. Drug Chem. Toxicol.
2010, 33, 209.
(834) Rao, M. V.; Purohit, A. R. Pharmacol. Pharm 2011, 2, 375.
(835) Thompson, C. M.; Markesbery, W. R.; Ehmann, W. D.; Mao,
Y. X.; Vance, D. E. Neurotoxicology 1988, 9, 1.
(836) Ehmann, W. D.; Markesbery, W. R.; Alauddin, M.; Hossain, T.
I.; brubaker, E. H. Neurotoxicology 1986, 7, 195.
(837) Saxe, S. R.; Wekstein, M. W.; Kryscio, R. J.; Henry, R. G.;
Cornett, C. R.; Snowdon, D. A.; Grant, F. T.; Schmitt, F. A.; Donegan,
S. J.; Wekstein, D. R.; Ehmann, W. D.; Markesbery, W. R. J. Am. Dent.
Assoc., JADA 1999, 130, 191.
(838) Roberts, H. W.; Charlton, D. G. Op. Dent. 2009, 34, 605.
(839) Barregard, L.; Sallsten, G.; Jarvholm, B. Occup. Environ. Med.
1995, 52, 124.
(840) Guzzi, G.; Grandi, M.; Cattaneo, C. Lancet 2002, 360, 2081.
(841) De Oliveira, M. T.; Pereira, J. R.; Ghizoni, J. S.; Bittencourt, S.
T.; Molina, G. O. Photomed. Laser Surg. 2010, 28, S111−S114.
(842) Robbins, D.; Boyle, K. Clin. Toxicol. 2011, 49, 586.
(843) Al-Saleh, I.; Al-Sedairi, A. Sci. Total Environ. 2011, 409, 3003.
(844) Eggleston, D. W.; Nylander, M. J. Prosthet. Dent. 1987, 58, 704.
(845) Nylander, M. Lancet 1986, 327, 442.
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Ann. N.Y. Acad. Sci. 1994, 717, 122.
(869) MacZurek, A.; Hager, K.; Kenklies, M.; Sharman, M.; Martins,
R.; Engel, J.; Carlson, D. A.; Münch, G. Adv. Drug Delivery Rev. 2008,
60, 1463.
(870) Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Munch,
G. Arch. Gerontol. Geriatr. 2001, 32, 275.
(871) Holmquist, L.; Stuchbury, G.; Berbaum, K.; Muscat, S.; Young,
S.; Hager, K.; Engel, J.; Münch, G. Pharmacol. Ther. 2007, 113, 154.
(872) Haenen, G. R.; Bast, A. Biochem. Pharmacol. 1991, 42, 2244.
(873) Moreira, P. I.; Harris, P. L. R.; Zhu, X.; Santos, M. S.; Oliveira,
C. R.; Smith, M. A.; Perry, G. J. Alzheimer's Dis. 2007, 12, 195.
(874) Epis, R.; Marcello, E.; Gardoni, F.; Longhi, A.; Calvani, M.;
Iannuccelli, M.; Cattabeni, F.; Canonico, P. L.; Di Luca, M. Eur. J.
Pharmacol. 2008, 597, 51.
(875) Shenk, J. C.; Liu, J.; Fischbach, K.; Xu, K.; Puchowicz, M.;
Obrenovich, M. E.; Gasimov, E.; Alvarez, L. M.; Ames, B. N.;
Lamanna, J. C.; Aliev, G. J. Neurol. Sci. 2009, 283, 199.
(876) Sheffner, A. L.; Medler, E. M.; Jacobs, L. W.; Sarett, H. P. Am.
Rev. Respir. Dis. 1964, 90, 721.
(877) Henke, M. O.; Ratjen, F. Paediatr. Respir. Rev. 2007, 8, 24.
(878) Garrett, C. E.; Prasad, K. Adv. Synth. Catal. 2004, 346, 889.
(879) Arakawa, M.; Ito, Y. Cerebellum 2007, 6, 308.
(880) Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.;
Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-
Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K. Q.; Bush, A. I.
Biol. Psychiatry 2008, 64, 361.
(881) Adair, J. C.; Knoefel, J. E.; Morgan, N. Neurology 2001, 57,
1515.
(882) Tchantchou, F.; Graves, M.; Rogers, E.; Ortiz, D.; Shea, T. B. J.
Alzheimer's Dis. 2005, 7, 135.
(883) Tucker, S.; Ahl, M.; Bush, A.; Westaway, D.; Huang, X.;
Rogers, J. T. Curr. Alzheimer Res. 2005, 2, 249.
(884) Mandel, S.; Amit, T.; Reznichenko, L.; Weinreb, O.; Youdim,
M. B. Mol. Nutr. Food Res. 2006, 50, 229.
(885) Khokhar, S.; Apenten, R. K. O. Food Chem. 2003, 81, 133.
(886) Le Nest, G.; Caille, O.; Woudstra, M.; Roche, S.; Burlat, B.;
Belle, V.; Guigliarelli, B.; Lexa, D. Inorg. Chim. Acta 2004, 357, 2027.
(887) Kumamoto, M; Sonda, T.; Nagayama, K.; Tabata, M. Biosci.,
Biotechnol., Biochem. 2001, 65, 126.
(888) Jovanovic, S. V.; Simic, M. G.; Steenken, S.; Hara, Y. J. Chem.
Soc., Perkin Trans. 2 1998, 11, 2365.
(889) Hynes, M. J.; Coinceanainn, M. O. J. Inorg. Biochem. 2001, 85,
131.
(890) Inoue, M. B.; Inoue, M.; Fernando, Q.; Valcic, S.;
Timmermann, B. N. J. Inorg. Biochem. 2002, 88, 7.
(891) Esparza, I.; Salinas, I.; Santamaria, C.; Garcia-Mina, J. M.;
Fernandez, J. M. Anal. Chim. Acta 2005, 543, 267.
(892) Rezai-Zadeh, K.; Shytle, D.; Sun, N.; Mori, T.; Hou, H.;
Jeanniton, D.; Ehrhart, J.; Townsend, K.; Zeng, J.; Morgan, D.; Hardy,
J.; Town, T.; Tan, J. J. Neurosci. 2005, 25, 8807.
(893) Rezai-Zadeh, K.; Arendash, G. W.; Hou, H.; Fernandez, F.;
Jensen, M.; Runfeldt, M.; Shytle, R. D.; Tan, J. Brain Res. 2008, 1214,
177.
(894) Lee, J. W.; Lee, Y. K.; Ban, J. O.; Ha, T. Y.; Yun, Y. P.; Han, S.
B.; Oh, K. W.; Hong, J. T. J. Nutr. 2009, 139, 1987.
(895) Hague, T.; Andrews, P. L.; Barker, J.; Naughton, D. P. Behav.
Pharmacol. 2006, 17, 425.
(896) Gupta, S. C.; Prasad, S.; Kim, J. H.; Patchva, S.; Webb, L. J.;
Priyadarsini, I. K.; Aggarwal, B. B. Nat. Prod. Rep. 2011, 28, 1937.
(897) Ng, T. P.; Chiam, P. C.; Lee, T.; Chua, H. C.; Lim, L.; Kua, E.
H. Am. J. Epidemiol. 2006, 164, 898.
(898) Pandav, R.; Belle, S. H.; DeKosky, S. T. Arch. Neurol. 2000, 57,
824.
(899) Lim, G. P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S. A.;
Cole, G. M. J. Neurosci. 2001, 21, 8270.
(900) Frautschy, S. A.; Hu, W.; Kim, P.; Miller, S. A.; Chu, T.; Harris-
White, M. E.; Cole, G. M. Neurobiol. Aging 2001, 22, 993.
(901) Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M.
R.; Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy,
S. A.; Cole, G. M. J. Biol. Chem. 2005, 280, 5892.
(902) Baum, L.; Ng, A. J. Alzheimer's Dis. 2004, 6, 367.
(903) Yoshida, H.; Okumura, N.; Nishimura, Y.; Kitagishi, Y.;
Matsuda, S. Exp. Ther. Med. 2011, 2, 629.
(904) Shytle, R. D.; Tan, J.; Bickford, P. C.; Rezai-Zadeh, K.; Hou, L.;
Zeng, J.; Sanberg, P. R.; Sanberg, C. D.; Alberte, R. S.; Fink, R. C.;
Roschek, B. Curr. Alzheimers Dis. 2012, 9, 500.
(905) Fiala, M.; Liu, P. T.; Espinosa-Jeffrey, A.; Rosenthal, M. J.;
Bernard, G.; Ringman, J. M.; Sayre, J.; Zhang, L.; Zaghi, J.; Dejbakhsh,
S.; Chiang, B.; Hui, J.; Mahanian, M.; Baghaee, A.; Hong, P.; Cashman,
J. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12849.
(906) Masoumi, A.; Goldenson, B.; Ghirmai, S.; Avagyan, H.; Zaghi,
J.; Abel, K.; Zheng, X.; Espinosa-Jeffrey, A.; Mahanian, M.; Liu, P. T.;
Hewison, M.; Mizwickie, M.; Cashman, J.; Fiala, M. J. Alzheimer's Dis.
2009, 17, 703.
(907) Zhang, L.; Fiala, M.; Cashman, J.; Sayre, J.; Espinosa, A.;
Mahanian, M.; Zaghi, J.; Badmaev, V.; Graves, M. C.; Bernard, G.;
Rosenthal, M. J. Alzheimer's Dis. 2006, 10, 1.
(908) Daniel, S.; Limson, J. L.; Dairam, A.; Watkins, G. M.; Daya, S.
J. Inorg. Biochem. 2004, 98, 266.
(909) Belkacemi, A.; Doggui, S.; Dao, L.; Ramassamy, C. Expert Rev.
Mol. Med. 2011, 13, e34.
(910) Larson, J.; Jessen, R. E.; Uz, T.; Arslan, A. D.; Kurtuncu, M.;
Imbesi, M.; Manev, H. Neurosci. Lett. 2006, 393, 23.
(911) Escames, G.; Lopez, A.; Garcia, J. A.; Garcia, L.; Acuna-
Castroviejo, D.; Garcia, J. J.; Lopez, L. C. Curr. Neuropharmacol. 2010,
8, 182.
(912) Zhou, J.; Zhang, S.; Zhao, X.; Wei, T. J. Pineal Res. 2008, 45,
157.
(913) Feng, Z.; Qin, C.; Chang, Y.; Zhang, J. T. Free Radical Biol.
Med. 2006, 40, 1010.
(914) Reiter, R. J.; Cabrera, J.; Sainz, R. M.; Mayo, J. C.; Manchester,
L. C.; Tan, D. X. Ann. N.Y. Acad. Sci. 1999, 890, 471.
(915) Espotito, E.; Cuzzocrea, S. Curr. Neuropharmacol. 2010, 8, 228.
(916) Pappolla, M. A.; Chyan, Y. J.; Poeggeler, B.; Frangione, B.;
Wilson, G.; ghiso, J.; Reiter, R. J. J. Neural Transm. 2000, 107, 203.
(917) Wang, X. CNS Neurosci. Ther. 2009, 15, 345.
(918) Wang, J. Z.; Wang, Z. F. Acta Pharmacol. Sin. 2006, 27, 41.
Chemical Reviews Review
dx.doi.org/10.1021/cr300009x | Chem. Rev. 2012, 112, 5193−52395237
(919) Bubenik, G. A.; Konturek, S. J. J. Physiol. Pharmacol. 2011, 62,
13.
(920) Sanchez-Barcelo, E. J.; Mediavilla, M. D.; Tan, D. X.; Reiter, R.
J. Curr. Med. Chem. 2010, 17, 2070.
(921) Liu, R. Y.; Zhou, J. N.; Van Heerikhuize, J.; Hofman, M. A.;
Swaab, D. F. J. Clin. Endocrinol. Metab. 1999, 84, 323.
(922) Ozcankaya, R.; Delibas, N. Croat. Med. J. 2002, 43, 28.
(923) Bidzan, L.; Grabowski, J.; Dutczak, B.; Bidzan, M. Psychiatr.
Pol. 2011, 45, 851.
(924) McCurry, S. M.; Pike, K. C.; Vitiello, M. V.; Logsdon, R. G.;
Larson, E. B.; Teri, L. J. Am. Geriatr. Soc. 2011, 59, 1393.
(925) Vecchierini, M. F. Psychol. Neuropsychiatr. Vieillissement 2010,
8, 15.
(926) Feng, Z.; Cheng, Y.; Zhang, J. T. J. Pineal Res. 2004, 37, 198.
(927) Spuch, C.; Antequera, D.; Fernańdez-Bachiller, M. I.;
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(943) Fernańdez-Bachiller, M. I.; Peŕez, C.; Campillo, N. E.; Paéz, J.
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A.; Guzman, C.; Jedenius, E.; Schaüble, B. Acta Neurol. Scand. 2011,
124, 302.
(949) Olin, J.; Schneider, L. Cochrane Database Syst. Rev. 2002, 4,
No. CD001747.
(950) Coyle, J. T.; Geerts, H.; Sorra, K.; Amatniek, J. J. Alzheimer's
Dis. 2007, 11, 491.
(951) Takata, K.; Kitamura, Y.; Saeki, M.; Terada, M.; Kagitani, S.;
Kitamura, R.; Fujikawa, Y.; Maelicke, A.; Tomimoto, H.; Taniguchi, T.;
Shimohama, S. J. Biol. Chem. 2010, 285, 40180.
(952) Levine, S. M. Bain Res 1997, 760, 298.
(953) Carrasco, J.; Giralt, M.; Molinero, A.; Penkowa, M.; Moos, T.;
Hidalgo, J. J. Neurotrauma 1999, 16, 1115.
(954) Lee, S. J.; Park, M. H.; Kim, H. J.; Koh, J. Y. Glia 2010, 58,
1186.
(955) Mocchegiani, E.; Malavolta, M.; Costarelli, L.; Giaconni, R.;
Cipriano, C.; Piacenza, F.; Tesei, S.; Basso, A.; Pierpaoli, S.; Lattanzio,
F. Proc. Nutr. Soc. 2010, 69, 290.
(956) Franceschi, C.; Valensin, S.; Lescai, F.; Olivieri, F.; Licastro, F.;
Grimaldi, L. M.; Monti, D.; De Benedictis, G.; Bonafe, M. Aging Clin.
Exp. Res. 2001, 13, 163.
(957) Nagano, S.; Satoh, M.; Sumi, H.; Fujimura, H.; Tohyama, C.;
Yanagihara, T.; Sakoda, S. Eur. J. Neurosci. 2001, 13, 1363.
(958) Puttaparthi, K.; Gitomer, W. L.; Krishnan, U.; Son, M.;
Rajendran, B.; Elliott, J. L. J. Neurosci. 2002, 22, 8790.
(959) Khayat, A.; Dencker, L. Acta Pharamacol. Toxicol 1984, 55,
145.
(960) Henriksson, J.; Tjalve, H. Environ. Res. 1998, 77, 130.
(961) Henriksson, J.; Tjalve, H. Toxicol. Sci. 2000, 55, 392.
(962) Henriksson, J.; Tjalve, H. Toxicol. Lett. 1997, 91, 153.
(963) Tallkvist, J.; Persson, E.; Henriksson, J.; Tjalve, H. Toxicol. Sci.
2002, 67, 108.
(964) Chan, J.; Huang, Z.; Merrifield, M. E.; Salgado, M. T.; Stillman,
M. J. Coord. Chem. Rev. 2002, 233, 319.
(965) Krezel, A.; Maret, W. Biochem. J. 2007, 402, 551.
(966) Eybl, V.; Kotyzova, D.; Koutensky, J.; Mickova, V.; Jones, M.
M.; Singh, P. K. Analyst 1998, 123, 25.
(967) Kepp, K. P. J. Inorg. Biochem. 2012, 107, 15.
(968) Ely, J. T. Bull. Environ. Contam. Toxicol. 2001, 67, 800.
(969) Exley, C. J. Inorg. Biochem. 1999, 76, 133.
(970) Richarz, A. N.; Bratter, P. Anal. Bioanal. Chem. 2002, 372, 412.
(971) Mocchegiani, E.; costarelli, L.; Giacconi, R.; Cipriano, C.; Muti,
E.; Malavolta, M. Exp. Gerontol. 2006, 41, 1094.
(972) Truong-Tran, A. Q.; Carter, J.; Ruffin, R. E.; Zalewski, P. D.
Biometals 2001, 14, 315.
(973) Wheeler, J. M.; Guthrie, C. R.; Kraemer, B. C. Biochem. Soc.
Trans. 2010, 38, 973.
(974) Boom, A.; Authelet, M.; Dedecker, R.; Frederick, C.; Van
Heurck, R.; Daubie, V.; Leroy, K.; Pochet, R.; Brion, J. P. Biochim.
Biophys. Acta 2009, 1793, 1058.
(975) Kim, I.; Park, E. J.; Seo, J.; Ko, S. J.; Lee, J.; Kim, C. H.
Neuroreport 2011, 22, 839.
(976) Jin, Z.; El-Deiry, W. S. Cancer Biol. Ther. 2005, 4, 139.
(977) Harris, F: M.; Tesseur, I.; Brecht, W. J.; Xu, Q.; Mullendorff,
K.; Chang, S.; Wyss-Coray, T.; Mahley, R. W.; Huang, Y. J. Biol. Chem.
2004, 279, 3862.
(978) Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D. Mol.
Pharmacol. 2005, 68, 917.
(979) Thaler, F.; Minucci, S. Expert Opin. Drug Discovery 2011, 6,
393.
(980) Letechipia-Vallejo, G.; Gonzalez-Burgos, I.; Cervantes, M.
Arch. Med. Res. 2001, 32, 186.
(981) Wang, X.; Zhu, S.; Pei, Z.; Drozda, M.; Stavrovskaya, I. G.; Del
Signore, S. J.; Cormier, K.; Shimony, E. M.; Wang, H.; Ferrante, R. J.;
Kristal, B. S.; Friedlander, R. M. J. Neurosci. 2008, 28, 9473.
(982) Wang, X.; Figueroa, B. E.; Stavrovskaya, I. G.; Zhang, Y.; Zhu,
S.; Day, A. L.; Kristal, B. S.; Friedlander, R. M. Stroke 2009, 40, 1877.
(983) Alzuet, G.; Ferrer, S.; Borras, J.; Castineiras, A.; Solans, X.;
Font-Bardia, M. Int. J. Inorg. Organomet. Chem 1992, 11, 2849.
(984) Alzuet, G.; Casanova, J.; Ramirez, J. A.; Carugo, O. J. Inorg.
Biochem. 1995, 57, 219.
(985) Ronowska, A.; Gul-Hinc, S.; Bielarczyk, H.; Pawelczyk, T.;
Szutowicz, A. J. Neurochem. 2007, 103, 972.
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